paroxetine has been researched along with fluoxetine in 585 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.85) | 18.7374 |
| 1990's | 185 (31.62) | 18.2507 |
| 2000's | 222 (37.95) | 29.6817 |
| 2010's | 137 (23.42) | 24.3611 |
| 2020's | 36 (6.15) | 2.80 |
| Authors | Studies |
|---|---|
| Costanzo, MJ; Maryanoff, BE; McComsey, DF; Nortey, SO; Shank, RP; Vaught, JL | 1 |
| Blakely, RD; Groshan, K; Richelson, E; Tatsumi, M | 1 |
| Carlier, PR; Lo, MM; Lo, PC; Reynolds, IJ; Richelson, E; Sharma, TA; Tatsumi, M | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Chi, DY; Choe, YS; Chu, S; Jeong, KJ; Jin, C; Lee, BC; Lee, BS | 1 |
| Bosch, A; Del Castillo, JC; Del Río, J; Heras, B; Lasheras, B; Martínez-Esparza, J; Monge, A; Mourelle, M; Oficialdegui, AM; Orús, L; Palop, JA; Pérez-Silanes, S; Roca, J; Tordera, R | 1 |
| Chu, S; Jin, C; Lee, BS; Se Lee, B; Song, YS; Yoon Chi, D | 1 |
| Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J | 1 |
| Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A | 1 |
| Beno, BR; Catt, JD; Cunningham, MA; Denhart, DJ; Deskus, JA; Ditta, JL; Gao, Q; Higgins, MA; Lodge, NJ; Marcin, LR; Mattson, GK; Mattson, RJ; Molski, TF; Sloan, CP; Taber, MT | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Buck, LB; Petrascheck, M; Ye, X | 1 |
| Alfinito, P; Bray, J; Cohn, ST; Deecher, DC; Fensome, A; Johnston, G; Koury, E; Mahaney, PE; Marella, MA; McComas, CC; Nogle, L; Trybulski, EJ; Vu, AT; Ye, F; Zhang, P | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Jung, ME; Kang, SY; Kim, HJ; Kim, J; Kim, MJ; Kim, MS; Lee, J; Lee, KN; Lee, M; Lee, SH; Park, EJ; Park, WK; Seo, HJ; Son, EJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Bertekap, R; Bronson, J; Davis, C; He, H; Lelas, S; Macor, JE; Newton, A; Taber, M; Wallace, T; Westphal, R; Wu, YJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Bojarski, AJ; Bugno, R; Duszyńska, B; Hogendorf, A; Hogendorf, AS; Kurczab, R; Lenda, T; Pietruś, W; Satała, G; Staroń, J; Wantuch, A; Warszycki, D | 1 |
| Block, P; Fieve, RR; Peselow, ED; Robins, CJ; Sanfilipo, MP | 1 |
| Artigas, F; Ortiz, J | 1 |
| Difiglia, C; Fieve, RR; Peselow, ED; Sanfilipo, MP | 1 |
| Crewe, HK; Haddock, RE; Lennard, MS; Tucker, GT; Woods, FR | 1 |
| DeVane, CL | 1 |
| Johnson, AM; Tulloch, IF | 1 |
| Goodman, WK; McDougle, CJ; Price, LH | 1 |
| Anderer, P; Frey, R; Grünberger, J; Krupka, M; Saletu, B; See, WR | 1 |
| Baldwin, D; Bullock, T; Montgomery, D; Montgomery, S | 1 |
| Koe, BK; Lebel, LA; Welch, WM | 1 |
| Cool, DR; Ganapathy, V; Liebach, FH | 1 |
| Rickels, K; Schweizer, E | 1 |
| Westwick, F | 1 |
| Esnaud, H; Graham, D; Habert, E; Langer, SZ | 1 |
| Fuller, RW | 1 |
| Asberg, M; Eriksson, B; Mårtensson, B; Träskman-Bendz, L; Wägner, A | 1 |
| Smith, DF | 1 |
| Bergström, M; Eriksson, K; Marcusson, JO; Ross, SB | 1 |
| Doucet, E; Hamon, M; Laaris, N; Lanfumey, L; Laporte, AM; Le Poul, E | 1 |
| Janne, P; Lejeune, D; Reynaert, C; Vause, M; Zdanowicz, N | 1 |
| Bristow, LJ; Cunningham, JR; Hogg, JE; Hutson, PH; Longmore, J; Murray, F; Pearce, D; Razzaque, Z; Saywell, K; Tricklebank, MD | 1 |
| Rothschild, AJ | 1 |
| Baumann, P; Rochat, B | 1 |
| Preskorn, SH | 4 |
| Corbett, R; Kongsamut, S; Roehr, J; Woods, A | 1 |
| Anelli, M; Caccia, S; Codegoni, AM; Fracasso, C; Garattini, S | 1 |
| Finley, PR | 1 |
| Hyttel, J; Sánchez, C | 1 |
| Bushnell, WD; Kreider, MS; Oakes, R; Wheadon, DE | 1 |
| Gagiano, CA | 1 |
| Jaffe, IA | 1 |
| Blackburn, TP; de Biasi, V; Kennett, GA; Lightowler, S; Stevens, NC; Tulloch, IF; Wood, MD | 1 |
| Althof, SE | 1 |
| Helmeste, DM; Reist, C; Tang, SW; Vu, R | 1 |
| Iny, L; Luthe, L; Pecknold, JC; Ramdoyal, D | 1 |
| Segraves, RT | 1 |
| Hirschfeld, RM | 1 |
| Alexoff, DA; Chen, R; Dewey, SL; Ding, YS; Fowler, JS; Gatley, SJ; Pan, D | 1 |
| Abou-Saleh, MT; Burns, RA; Edwards, DR; Harrison, DA; Horton, RW; Katona, CL; Lawrence, KM; Lock, T; Nairac, BL; Robertson, MM | 1 |
| Ludwig, M; Schöne, W | 2 |
| Alpert, JE; Fava, M; Maddocks, A; Rosenbaum, JF | 1 |
| Preskorn, S | 1 |
| Deltito, JA | 1 |
| Berendsen, HH; Broekkamp, CL | 1 |
| Asai, K; Mori, H; Nankai, M; Toru, M; Watanabe, A; Yamada, S; Yoshimoto, S | 1 |
| Cline, EJ; Kim, S; Kuhar, MJ; Scheffel, U | 1 |
| Tignol, J | 1 |
| Brøsen, K | 1 |
| Iacono, RP; Toyama, SC | 1 |
| Böhmer, F; Geretsegger, C; Ludwig, M | 1 |
| Cheng, CH; Costall, B; Naylor, RJ; Rudd, JA | 1 |
| Hrdina, PD; Vu, TB | 1 |
| Cumming, P; Gjedde, A | 1 |
| Andrews, AM; Murphy, DL | 1 |
| Gerber, J; Jimerson, D; Salzman, C; Vasile, R; Watsky, E | 1 |
| Arora, RC; Crayton, JW; Fichtner, CG; O'Connor, FL | 1 |
| Cadogan, AK; Kendall, DA; Marsden, CA; Tulloch, I | 1 |
| Kupfer, DJ | 1 |
| Bartholomé, F; De Wilde, J; Leyman, S; Mertens, C; Schotte, G; Spiers, R | 1 |
| Bymaster, FP; Krushinski, JH; Mayle, DA; Reid, LR; Robertson, DW; Wong, DT | 1 |
| Dewar, KM; Grondin, L; Nénonéné, EK; Ohayon, M; Reader, TA | 1 |
| Crosby, J; Flint, AJ; Genik, JL | 1 |
| LaBranche, S | 1 |
| Hsu, JH; Shen, WW | 1 |
| Burke, MJ; Harvey, AT; Preskorn, SH | 1 |
| Cole, JO; Diamond, L; Pillay, SS; Stoll, AL; Workum, SB | 1 |
| Blier, P; Bouchard, C; el Mansari, M | 1 |
| Joffe, RT; Levitt, AJ; Sokolov, ST; Young, LT | 1 |
| Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Volpicelli, SA | 1 |
| Newhouse, PA | 1 |
| Hunter, KD; Wilson, WS | 1 |
| Childers, SR; Davies, HM; Kuhn, LA; Matasi, JJ; Sexton, T; Thornley, C | 1 |
| Chiba, K; Ishizaki, T; Kobayashi, K; Kuroiwa, Y; Tani, M; Yamamoto, T | 1 |
| Balon, R | 2 |
| Knowles, SR; Liu, BA; Mittmann, N; Shear, NH | 1 |
| Abraham, P; Blough, BE; Boja, JW; Carroll, FI; Kuhar, MJ; Lewin, AH | 1 |
| Harvey, AT; Preskorn, SH | 2 |
| Cua, W; Dominguez, RA; Kumar, AM | 1 |
| Reynolds, CF | 1 |
| Abraham, P; Boja, JW; Carroll, FI; Holmquist, CR; Keverline-Frantz, KI; Kuhar, MJ | 1 |
| Brøsen, K; Gram, LF; Jeppesen, U; Loft, S; Poulsen, HE; Vistisen, K | 1 |
| Carpenter, LL; Epperson, CN; McDougle, CJ; Price, LH | 1 |
| Cooper, TB; Costa, E; Guidotti, A; Uzunov, DP | 1 |
| Leo, RJ | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Harnett-Sheehan, K; Sheehan, DV | 1 |
| de Vet, HC; Hartmans, M; Honig, A; Menting, JE; Rozendaal, N; van Praag, HM; Verhey, FR | 1 |
| Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S | 1 |
| Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM | 1 |
| Baumann, P; Eap, CB | 1 |
| MacKay, AV; Price, JS; Waller, PC; Wood, SM | 1 |
| Almdal, TP; Christensen, O; Sørensen, HA | 1 |
| Bauer, M; Baumgartner, A; Hellweg, R | 1 |
| Bakish, D; Cavazzoni, P; Chudzik, J; Hrdina, PD; Ravindran, A | 1 |
| Alonso, M; Rapaport, MH; Val, E | 1 |
| Rifkin, A | 1 |
| Meier, E; Sánchez, C | 1 |
| Rey, JM; Wever, C | 1 |
| Charness, WE; Ferrando, SJ; Goldman, JD | 1 |
| Earley, B; Faherty, CJ; Leonard, BE | 1 |
| Devine, CL; Markowitz, JS | 1 |
| Black, KJ; Sheline, YI | 1 |
| DePalma, RL; Katholi, CR; Modell, JD; Modell, JG | 1 |
| Besnard, JC; Boazi, M; Bricard, J; Caillet, M; Chalon, S; Emond, P; Frangin, Y; Garreau, L; Guilloteau, D; Mauclaire, L | 1 |
| Ayonrinde, OT; Sanfilippo, FM | 1 |
| De Vry, J; Maurel, S; Schreiber, R | 2 |
| Darby, AL; Lesser, IM; Miller, BL; Swartz, JR | 1 |
| Constantino, JN; Kincaid, M; Liberman, M | 1 |
| Ahern, D; Ball, SE; Kao, J; Scatina, J | 1 |
| Adès, J; Lejoyeux, M | 1 |
| Haddad, P | 1 |
| Bennett-Clarke, CA; Chiaia, NL; Rhoades, RW | 1 |
| Bordet, R; Dupuis, B; Thomas, P | 1 |
| Mitchell, S; Tracy, KA; Zajecka, J | 1 |
| Alderman, CP; Hundertmark, JD; Soetratma, TW | 1 |
| Bousoño, M; Calcedo, A; Carrasco, JL; Ciudad, J; Daniel, E; De la Gandara, J; Derecho, J; Franco, M; Gomez, MJ; Izquierdo, JA; Ledesma, A; Llorca, G; Macias, JA; Martin, T; Montejo-González, AL; Perez, V; Sanchez, JM; Sanchez, S; Vicens, E | 1 |
| Richelson, E | 1 |
| Boyer, W | 1 |
| Auerbach, SB; Gundlah, C; Heal, DJ; Martin, KF | 1 |
| Gregor, KJ; James, SP; Way, K; Young, CH | 1 |
| Gorman, JM | 1 |
| Avor, K; Basmadjian, GP; Chan, HM; Hall, N; Seale, TW; Singh, S | 1 |
| Cohen, CI; Trappler, B | 1 |
| O'Connor, M; Silver, H | 1 |
| Edwards, IR; Fletcher, AP; Lindquist, M; Pettersson, M; Sanderson, JH; Schou, JS; Stahl, MM; Taylor, NF | 1 |
| Buesching, DP; Croghan, TW; Crown, WH; Heiligenstein, JH; Hylan, TR; Melfi, CA; Meneades, L | 2 |
| Amsterdam, JD; Garcia-España, F; Goodman, D; Hooper, M; Hornig-Rohan, M | 1 |
| Fawcett, J; Mitchell, S; Zajecka, J | 1 |
| Grimes, JB; Hines, A; Labbate, LA; Pollack, MH | 1 |
| Shepherd, J; Strachan, J | 1 |
| Andrews, W; Barrett, E; Parker, G | 1 |
| Arana, GW; Grimes, JB; Labbate, LA | 1 |
| Ascroft, RC; Fava, M; Hoog, SL; Krebs, WB; Rosenbaum, JF | 1 |
| McReynolds, AM; Meyer, JS | 1 |
| Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P | 1 |
| Hengeveld, MW; Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Bourin, M; Redrobe, JP | 1 |
| Roose, SP; Suthers, KM | 1 |
| Benvenga, MJ; Dreshfield, L; Fuller, RW; Gehlert, DR; Gleason, S; Hemrick-Luecke, SK; Tinsley, F; Wong, DT | 1 |
| Barbey, JT; Roose, SP | 1 |
| Bhaumik, S; Branford, D; Naik, B | 1 |
| Arlinghaus, KA; Clearman, RR; George, MS; Kotrla, KJ; Nahas, Z | 1 |
| Pollock, BG | 1 |
| Thompson, C | 2 |
| Burke, WJ; Frank, MG; Hendricks, SE; Johnson, DR; Wieseler, JL | 1 |
| Stahl, SM | 1 |
| Amsterdam, JD; Deltito, JA; Dunner, DL; Fava, M; Salzman, C; Schwaller, M | 1 |
| Barton, CL; Hutson, PH | 1 |
| Harkin, A; Kelly, JP; Leonard, BE; Redmond, AM | 1 |
| Voris, JC | 1 |
| Navarro, R; Spangler, M; Valler, WE | 1 |
| Begg, EJ; Sainsbury, R; Wilkinson, TJ; Winter, AC | 1 |
| Alvarez, E; Artigas, F; Pérez, V; Puigdemont, D; Soler, J | 1 |
| Alfaro, CL; Ereshefsky, L; Lam, YW; Simpson, J | 2 |
| Nelson, JC; Ostroff, RB | 1 |
| Farah, A | 1 |
| Bagli, M; Huether, G; Moll, GH; Rothenberger, A; Rüther, E; Wegerer, V | 1 |
| Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP | 1 |
| Kristensen, AS; Mortensen, OV; Rudnick, G; Wiborg, O | 1 |
| Boyer, P | 1 |
| Nutt, DJ | 1 |
| Gaebel, W; Janz, A; Klimke, A; Larisch, R; Müller-Gärtner, HW; Vosberg, H | 1 |
| Lurcott, G | 1 |
| Salama, AA; Salama, SA | 1 |
| Carleborg, L; Hägg, S; Ohman, R; Spigset, O | 1 |
| Sheehan, DV | 1 |
| Hensley, PL; Nurnberg, HG; Paine, SS; Thompson, PM | 1 |
| Galin, RS; Robison, LM; Sclar, DA; Skaer, TL | 1 |
| Hensley, PL; Nurnberg, HG; Thompson, PM | 1 |
| Berndt, ER; Colucci, S; Grudzinski, AN; Miceli, R; Russell, JM | 1 |
| Griffin, LD; Mellon, SH | 1 |
| Seiden, LS; Sokolowski, JD | 1 |
| Bugge, A; Kristoffersen, L; Lundanes, E; Slørdal, L | 1 |
| Alvarez, JC; Arnulf, I; Gluck, N; Launay, JM; Leboyer, M; Pecquery, R; Perez-Diaz, F; Quintin, P; Spreux-Varoquaux, O | 1 |
| McMahon, CG; Samali, R | 1 |
| Amsterdam, J; Apter, J; Fava, M; Londborg, P; Michelson, D; Pagh, L; Tamura, R | 1 |
| Härtter, S; Hiemke, C | 1 |
| Bock, N; Huether, G; Mehnert, C; Moll, GH; Rothenberger, A; Rüther, E; Wicker, M | 1 |
| Anisman, H; Griffiths, J; Merali, Z; Ravindran, AV; Zaharia, MD | 1 |
| Davidson, JR | 1 |
| Garcìa-Rodrìguez, JA; Munoz-Bellido, JL; Munoz-Criado, S | 1 |
| Han, JH; Kim, SC; Lee, MY; Seo, KK | 1 |
| Knight, DL; Nemeroff, CB; Owens, MJ | 1 |
| Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR | 1 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Amsterdam, J; Apter, J; Fava, M; Londborg, P; Michelson, D; Tamura, R; Tepner, RG | 1 |
| Fava, M; Hoog, SL; Kopp, JB; Nilsson, ME; Rosenbaum, JF; Tepner, RG | 1 |
| Gentilini, G; Lopez-Silva, S; Lucca, A; Soldarini, A | 1 |
| Anthony, JP; Neumaier, JF; Sexton, TJ | 1 |
| Cheetham, SC; Heal, DJ; Slater, NA; Viggers, JA | 1 |
| Berreira, PJ; Cohen, BM; Henry, ME; Kaufman, MJ; Michelson, D; Moore, CM; Renshaw, PF; Schmidt, ME; Stoddard, E; Vuckevic, AJ | 1 |
| Baier, D; Kohnen, R; Philipp, M; Tiller, JW | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Broft, A; Laruelle, M; Martinez, D | 1 |
| Deslandes, PN; Pache, DM; Sewell, RD; Subhan, F | 1 |
| Fava, M; Hoog, SL; Judge, R; Koke, SC; Nilsson, ME | 1 |
| Terao, T | 1 |
| Fitzgerald, F; Glod, CA; Lynch, A | 1 |
| Antonelli, T; Bebe, BW; Ferraro, L; Fuxe, K; Rambert, FA; Tanganelli, S; Tomasini, MC | 1 |
| Birnbaum, AK; Nelson, MH; Remmel, RP | 1 |
| Dewa, CS; Goering, P; Hoch, JS | 1 |
| Cook, IA; Leuchter, AF | 1 |
| Agid, O; Lerer, B; Shalev, AY | 1 |
| Hause, S; Huether, G; Moll, GH; Rothenberger, A; Rüther, E | 1 |
| Panzarino, PJ; Xuan, J | 1 |
| Borsini, F; Brambilla, A; Cesana, R; Grippa, N | 1 |
| Kim, SC; Lee, MY; Seo, KK | 1 |
| Kremer, C; Quitkin, FM; Taylor, BP | 1 |
| Balsitis, M; Harrison, BJ; Wallace, WA | 1 |
| Emslie, GJ; Mayes, TL | 1 |
| Baerg, EA; Garland, EJ | 1 |
| Bergsholm, YK; Bøhler, E; Nordeng, H; Spigset, O | 1 |
| Baruch, Y; Chelben, J; Lustig, M; Strous, RD | 1 |
| Camarero, J; Colado, MI; Esteban, B; Green, AR; Peter, MJ; Sanchez, V | 1 |
| Perry, CM; Wellington, K | 1 |
| Berthoz, A; Chapouthier, G; Jouvent, R; Lepicard, EM; Rudrauf, D; Venault, P | 1 |
| Antonucci, G; Bragoni, M; Coiro, P; De Angelis, D; Grasso, MG; Morelli, D; Paolucci, S; Rizzi, F; Troisi, E | 1 |
| Clary, CM; Colucci, SV; Grudzinski, AN; Miceli, RJ; Roy-Byrne, PP; Xu, Y | 1 |
| Cooper, J; Greenslade, RG; Mitchell, SN | 1 |
| Dolor, R; Eckert, GJ; Gilsenan, A; Hays, R; Kroenke, K; Stang, P; Swindle, R; Weinberger, M; West, SL; Zhou, XH | 1 |
| Greibrokk, T; Kristoffersen, L; Lundanes, E; Molander, P; Thomassen, A | 1 |
| Neel, JL; Stevens, VM; Stewart, JE | 1 |
| Bauer, MS; Glick, HA; Onesirosan, P; Polsky, D | 1 |
| Barnes, NM; Blakely, RD; Bowery, NG; Chamba, A; Gordon, J; Grafton, G; Gregory, CD; Serafeim, A | 1 |
| Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME | 1 |
| Boulton, DW; DeVane, CL; Goldman, J; Liston, HL; Markowitz, JS; Risch, SC | 1 |
| Fonseca, R; Tefferi, A | 1 |
| Baker, GB; Kennedy, SH; Masellis, M; McCann, SM; McIntyre, RS; McKay, G; Raskin, J | 1 |
| Brown, EB; Gonzales, JS; Miner, CM; Munir, R | 1 |
| Bellino, S; Bogetto, F; Patria, L; Revello, RB | 1 |
| Dane, FC; Elliott, RL | 1 |
| Stopa, SF | 1 |
| Culpepper, L; Heeren, T | 1 |
| Keeley, R | 1 |
| Cronholm, P; Straton, JB | 1 |
| Rehavi, M; Roz, N; Weizman, A | 1 |
| Cassano, GB; Puca, F; Scapicchio, PL; Trabucchi, M | 1 |
| Cullen, N; Lexell, J; Zafonte, RD | 1 |
| Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J | 1 |
| Jacobson, JG; Judge, R; Parry, MG; Quail, D | 1 |
| Kline, NA; Matloff, JL; Stein, MB | 1 |
| Begg, EJ; Kennedy, MA; Roberts, R; Stedman, CA; Wilkinson, TJ | 1 |
| De La Fuente, JA; De Las Cuevas, C; Sanz, EJ | 1 |
| Entsuah, R; Rudolph, RL; Stahl, SM | 1 |
| Marsden, CA; Mason, R; Muchimapura, S | 1 |
| Croghan, TW; McCombs, JS; Shi, L; Stimmel, GL | 1 |
| Beyer, CE; Boikess, S; Dawson, LA; Luo, B | 1 |
| Barreira, PJ; Cohen, BM; Hennen, J; Henry, ME; Kaufman, MJ; Michelson, D; Renshaw, PF; Schmidt, ME; Stoddard, E; Vukovic, AJ | 1 |
| Barnes, NM; Bunce, CM; Chamba, A; Drayson, MT; Gordon, J; Grafton, G; Gregory, CD; Holder, MJ; Luong, QT; Serafeim, A | 1 |
| Anderson, TA; Dobscha, SK; Hauser, P; Hoffman, WF; Snodgrass, LS; Turner, EH; Winterbottom, LM | 1 |
| Bertelsen, KM; Greenblatt, DJ; Obach, RS; Venkatakrishnan, K; Von Moltke, LL | 1 |
| Lima, L; Urbina, M | 1 |
| Carreira, I; Lima, L; Piñango, L; Pineda, S; Urbina, M | 1 |
| Jureidini, JN; Tonkin, AL | 1 |
| Lo Sasso, AT; Sheffield, RE; Way, K; Young, CH | 1 |
| Altshuler, LL; Haynes, D; Hendrick, V; Hwang, S; Lee, E; Stowe, ZN | 1 |
| Agid, O; Lerer, B | 1 |
| Pan, GZ; Qian, JM; Wang, WA | 1 |
| Connor, TJ; Harkin, A; Kelly, JP; Shanahan, E | 1 |
| Varley, CK | 1 |
| Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA | 1 |
| Lebert, F | 1 |
| Broocks, A; Hohagen, F; Kordon, A | 1 |
| Akin, A; Chaturvedi, AK | 1 |
| Ansseau, M; Broly, F; Charlier, C; Lhermitte, M; Pinto, E; Plomteux, G | 1 |
| Goetz, MP; Loprinzi, CL | 1 |
| Masuda, Y; Shimizu, T | 1 |
| Altamirano, AV; Benmansour, S; Frazer, A; Gould, GG; Jones, DJ; Morilak, DA; Pardon, MC; Sanchez, TA | 1 |
| Kim, SW; Lee, SH; Paick, JS | 1 |
| Anand, A; Berman, RM; Charney, DS; Lynch-Colonese, K; Perry, EB; Sanacora, G | 1 |
| Swedo, S; Vitiello, B | 1 |
| Bateman, DN; Chick, J; Good, AM; Kelly, CA; Masterton, G | 1 |
| Bergan, A; Chopra, MP; Crits-Christoph, P; DeRubeis, RJ; Gallop, R; O'Reardon, JP | 1 |
| Carella, A; Cheok, A; Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Potter, WZ; Sagrati, S; Spencer, EP; Wilson, AA | 1 |
| Cryan, JF; Dalvi, A; Friedland, JC; Hirsch, BR; Jin, SH; Lucki, I; O'Leary, OF; Ouyang, M; Page, ME; Thomas, SA | 1 |
| Brown, EB; Joliat, MJ; Miner, CM | 1 |
| Simons, J | 1 |
| Eckert, G; Greco, T; Kroenke, K | 1 |
| Hemrick-Luecke, SK; Iyengar, S; Simmons, RM; Webster, AA; Xu, JY | 1 |
| Jick, H; Jick, SS; Kaye, JA | 1 |
| Kramer, TA | 1 |
| Agren, H; Hägglöf, B; Lundin, B; Waern, M | 1 |
| Eichner, SF; Jones, JR; Moore, ML | 1 |
| Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ | 1 |
| Carey, GJ; Gold, LH; Nielsen, DM | 1 |
| Armbrust, KL; Black, MC; Henry, TB; Kwon, JW | 1 |
| Anand, A; Baldwin, RM; Bozkurt, A; Charney, D; Innis, RB; Khan, S; Kugaya, A; Malison, RT; Sanacora, G; Seibyl, JP; Staley, JK; Van Dyck, CH | 1 |
| Hirano, K; Kagawa, Y; Kimura, R; Maruyama, S; Yamada, S | 1 |
| Albert, U; Bogetto, F; Maina, G; Salvi, V | 1 |
| Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN | 1 |
| Barbui, C | 1 |
| Calviño, MA; Iscla, IR; Szczupak, L | 1 |
| Ahn, BO; Ahn, GJ; Hwang, WS; Kang, KK; Kang, SK; Kim, DS; Kim, WB; Lee, BC | 1 |
| Hashimoto, H; Hirano, K; Kato, Y; Kimura, R; Sugimoto, Y; Uchida, S; Yamada, J; Yamada, S | 1 |
| Argyropoulos, S; Hale, AS; Willner, P | 1 |
| Huande, L; Juan, H; Zhiling, Z | 1 |
| Egberts, AC; Heerdink, ER; Hugtenburg, JG; van Geffen, EC; van Hulten, RP | 1 |
| Entsuah, R; Padmanabhan, SK; Shelton, C; Vinall, PE | 1 |
| Cyranowski, JM; Fagiolini, A; Frank, E; Kupfer, DJ; Scott, J; Shear, MK; Swartz, H | 1 |
| Pei, Q; Sharp, T; Tordera, RM | 1 |
| Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M | 1 |
| Briley, KA; Goodale, ES; Gopal, KV; Hendea, OM | 1 |
| Goldney, RD | 1 |
| de Romemont, E; Gambier, N; Gillet, P; Muller, JC; Petitpain, N | 1 |
| Boerngen-Lacerda, R; Goeldner, FO; Machado, HB; Pigatto, G; Ribeiro, AF | 1 |
| Bonikovski, V; Futuro-Neto, HA; Pires, JG | 1 |
| Carrasco, JL; Sandner, C | 1 |
| Benturquia, N; Haddjeri, N; Mansari, ME; Mnie-Filali, O; Sánchez, C; Wiborg, O | 1 |
| Albertazzi, P | 1 |
| Berger, U; Jensen, E; Kallenborn, R; Samuelsen, PJ; Vasskog, T | 1 |
| de Abajo, FJ; Madurga, M; Montero, D; Rodríguez, LA | 1 |
| Dinan, TG; O'Brien, SM; Scott, LV | 1 |
| Hogg, S; Jessa, M; Michan, L | 1 |
| Ishii, S; Ito, T; Kaneko, Y; Kashiwa, A; Nishikawa, T; Umino, A | 1 |
| Kim, YK; Lee, KM | 1 |
| Belmaker, RH; Nemets, B; Shapira, B; Trachtenberg, A | 1 |
| Healy, D | 1 |
| Cookson, J; Desaiah, D; Gilaberte, I; Kajdasz, DK | 1 |
| de Jong-van den Berg, L; Egberts, T; Kaasenbrood, H; Schobben, F; Ververs, T; Visser, G | 1 |
| Greenhill, LL; Moreno, C; Roche, AM | 1 |
| de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P | 1 |
| Lathi, RB; Shahine, LK | 1 |
| Bailly, D | 1 |
| Eastwood, BJ; Jones, CK; Need, AB; Shannon, HE | 1 |
| Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D | 1 |
| Allain, H; Bentué-Ferrer, D; Bourin, M; Drapier, D; Laviolle, B; Millet, B; Reymann, JM | 1 |
| Ashby, CR; Blackburn, TP; Ramachandran, PV; Sekine, Y; Suzuki, K | 1 |
| Lunde, H; Lunder, N; Molden, E; Refsum, H | 1 |
| Calgüneri, M; Ertenli, I; Kaymak, SU; Kiraz, S; Onat, AM; Ozçakar, L; Oztürk, MA; Ureten, K | 1 |
| Choi, J; Golbeck, AL; Neff, M; Preskorn, SH; Shah, R | 1 |
| Rybakowski, JK; Łojko, D | 1 |
| Alexander, IM; Moore, A | 1 |
| Li, SJ; Liu, T | 1 |
| Dobkin, RD; Marin, H; Menza, MA | 1 |
| Connor, K; Davidson, JR; Vaishnavi, S | 1 |
| Detke, MJ; Faries, DE; Mallinckrodt, CH; Meyers, AL; Prakash, A | 1 |
| Dingwall, K; Douglas, J; Jorgenson, G; Smith, SS | 1 |
| Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G | 1 |
| Chu, S; Metcalfe, CD | 1 |
| Hetrick, S; McKenzie, J; Merry, S; Proctor, M; Sindahl, P | 1 |
| Gross, G; Groth, I; Jongen-Relo, A; Rex, A; Wicke, KM | 1 |
| Edwards, JL; Kirk, KK; Midha, CK | 1 |
| Altunayoglu, V; Boz, C; Gazioglu, S; Hocaoglu, C | 1 |
| Bekele, NB; Shih, YC; Xu, Y | 1 |
| Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME | 1 |
| Busto, G; Di Spigno, D; Falcini, R; Salvati, L; Tundo, A | 1 |
| Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J | 1 |
| Detke, MJ; Fava, M; Houston, JP; Mallinckrodt, CH; Prakash, A; Swindle, R | 1 |
| Borah, M; Radhakrishnan, M; Ramamoorthy, R | 1 |
| Abebe, K; Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Hughes, C; Iyengar, S; Keller, M; Kennard, B; Leonard, H; McCracken, J; Melhem, N; Onorato, M; Porta, G; Ritz, L; Ryan, N; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J | 1 |
| Holman, JR; Kimmer, SL; Lo, V; Mercado, MG; Wanserski, G | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
| Ermani, M; Freo, U; Merico, A; Ori, C | 1 |
| Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R | 1 |
| Kelly, BD | 1 |
| Bespalov, AY; Gross, G; Mezler, M; Schoemaker, H; Sukhotina, IA; van Gaalen, MM; Wicke, K | 1 |
| Avgil, M; Clementi, M; Di Gianantonio, E; Diav-Citrin, O; Ornoy, A; Schaefer, C; Shechtman, S; Wajnberg, R; Weber-Schoendorfer, C; Weinbaum, D | 1 |
| Durkin, S; Harkin, A; Prendergast, A | 1 |
| Amitani, H; Asakawa, A; Fujimiya, M; Fujitsuka, N; Hayashi, M; Inui, A; Kojima, S; Sameshima, M | 1 |
| Billups, SJ; Delate, T; Dugan, D | 1 |
| Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Iyengar, S; Keller, M; Kennard, B; Leonard, H; Mayes, T; McCracken, J; Porta, G; Ritz, L; Ryan, N; Shamseddeen, W; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD | 1 |
| Farooqui, AA; Lee, LH; Ong, WY; Shui, G; Tan, CH; Wenk, MR | 1 |
| Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J | 1 |
| Davidson, S; Gil-Ad, I; Harell, D; Maayan, R; Prokonov, D; Taler, M; Weizman, A | 1 |
| Croghan, TW; Daniel, G; Erder, MH; Esposito, D; Stoto, MA; Wahl, P | 1 |
| Hasegawa, R; Ikeda, K; Karasawa, J; Tamura, K; Yamamoto, H; Yamamoto, T; Yasumoto, S | 1 |
| Aburakawa, Y; Aizawa, H; Hasebe, N; Kwak, S; Sawada, J; Yamashita, T | 1 |
| Ahrold, TK; Meston, CM | 1 |
| Carrilho, E; Catai, AP; Lanças, FM; Queiroz, ME | 1 |
| Bertoletti, E; Chilovi, BV; Conti, M; Padovani, A; Rozzini, L; Trabucchi, M; Zanetti, M | 1 |
| Huhtala, H; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Mononen, N; Poutanen, O; Setälä-Soikkeli, E; Viikki, M | 1 |
| Bhatt, M; Shah, S | 1 |
| Anderssen, T; Bergersen, O; Eggen, T; Jensen, E; Vasskog, T | 1 |
| Lanza di Scalea, T; Wisner, KL | 1 |
| Sussman, N | 1 |
| Berant, M; Birk, E; Klinger, G; Linder, N; Merlob, P; Sirota, L; Stahl, B | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Ozyavuz, R; Yaris, E | 1 |
| Brent, DA | 1 |
| Annerbrink, K; Eriksson, E; Hedner, J; Olsson, M | 1 |
| DeVeaugh-Geiss, AM; Gaynes, BN; Kroenke, K; Miller, WC; Sleath, B; West, SL | 1 |
| Arias, HR; Bhumireddy, P; Feuerbach, D; Ortells, MO | 1 |
| Drummer, OH; Gerostamoulos, D; Pilgrim, JL | 1 |
| Gricar, J; Rendas-Baum, R; Wallenstein, GV; Yang, M | 1 |
| Charles, D; Fava, M; Papakostas, GI | 1 |
| Jenkinson, ML | 1 |
| Dormuth, CR; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Dormuth, C; Lee, JC; Mehta, J; Miller, M; Patrick, AR; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Ellfolk, M; Malm, H | 1 |
| Arias, HR; Feuerbach, D; Jozwiak, K; Russell, M; Targowska-Duda, KM | 1 |
| Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P | 1 |
| Bishop, JR; Ellingrod, VL; Keiser, MJ; Thomas, KL | 1 |
| Mochcovitch, MD; Nardi, AE | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Corona, T; Fornai, M; Mantarro, S; Montagnani, S; Pergola, A; Ruggiero, E; Scollo, C; Testi, A; Tuccori, M | 1 |
| Kaneko, S; Kitagawa, Y; Kitaichi, M; Nagayasu, K; Nakagawa, T; Shirakawa, H; Yatani, Y | 1 |
| Choi, HC; Kang, TC; Kim, DS; Kim, JE; Kim, YI; Song, HK | 1 |
| Fischer, K; Goetghebeur, E; Vrijens, B; White, IR | 1 |
| Goldman, SA; Hertz, L; Li, B; Lovatt, D; Nedergaard, M; Peng, L; Song, D; Xu, J; Zhang, S | 1 |
| Castberg, I; Davies, SJ; Lennard, MS; Lewis, G; Spigset, O; Taylor, S; Westin, AA | 1 |
| Dobzhenko, MN; Shchepotin, IB; Zotov, AS | 1 |
| Cheng, FC; Feng, JJ; Lin, CH; Wei, JW; Yang, SD | 1 |
| Kourti, PV; Samanidou, VF | 1 |
| Akulova, VK; Fedotova, IuO; Ordian, NÉ; Pivina, SG | 1 |
| Beste, J; Blackwell, JC; Patel, BN | 1 |
| Artama, M; Gissler, M; Malm, H; Ritvanen, A | 1 |
| Akulova, VK; Fedotova, YO; Ordian, NÉ; Pivina, SG | 1 |
| Cuestas, E; Cuestas, ME | 1 |
| Bozzo, P; Koren, G; Pupco, A | 1 |
| Molden, E; Spigset, O | 1 |
| Dasgupta, K; Labos, C; Nedjar, H; Rahme, E; Turecki, G | 1 |
| Graham, DL; Morford, LR; Skelton, MR; Vorhees, CV; Williams, MT | 1 |
| Chamielec, M; Gałecki, P; Talarowska, M; Zboralski, K | 1 |
| Einarson, A; Puryear, LJ; Spinelli, M | 1 |
| Evans, S; Gilbert, R; Nazareth, I; Petersen, I | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, GJ; Keller, MB; Porta, G; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Maraschin, M; Rodrigues, AL; Tasca, CI; Zeni, AL; Zomkowski, AD | 1 |
| Haneda, E; Higuchi, M; Kobayashi, K; Suhara, T; Suzuki, H | 1 |
| Egashira, N; Fujiwara, M; Iwasaki, K; Mishima, K; Nagao, M; Oishi, R; Okuno, R; Shirakawa, A | 1 |
| Dahmen, N; Engel, A; Gerbaulet, M; Hiemke, C | 1 |
| Barbato, A; Bortolotti, A; D'Avanzo, B; Fortino, I; Franchi, C; Merlino, L; Nobili, A; Parabiaghi, A; Tettamanti, M | 1 |
| Mandrioli, R; Mercolini, L; Raggi, MA; Saracino, MA | 1 |
| Kovatsi, L; Livanos, A; Njau, S; Pantazidou, K; Samanidou, V | 1 |
| Cortés, JM; Hidalgo, M; Jönsson, JÅ; Larsson, E; Sagristà, E; Salvadó, V | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Koesters, M; Nosè, M; Omori, IM; Purgato, M; Trespidi, C | 1 |
| Choi, SJ; Hahn, SJ; Hong, YJ; Kim, HJ; Kim, TH; Rhie, DJ; Sung, KW; Yang, JS; Yoon, SH | 1 |
| Humpston, CS; Robinson, ES; Wood, CM | 1 |
| Cox, GR; Hetrick, SE; McKenzie, JE; Merry, SN; Simmons, MB | 1 |
| Claxton, A; Hackett, ML; Hankey, GJ; Hsieh, CF; Kutlubaev, MA; Lee, R; Mead, GE | 1 |
| Boura-Halfon, S; Gurevitch, D; Isaac, R; Levkovitz, Y; Shainskaya, A; Zick, Y | 1 |
| Campos-Torres, A; Haase, J; Malynn, S; Moynagh, P | 1 |
| Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E | 1 |
| Gorman, DA; Lam, D; Patten, S; Pringsheim, T | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Bannink, M; Binkhorst, L; Jager, A; Mathijssen, RH; van Gelder, T; van Herk-Sukel, MP; Wiemer, EA | 1 |
| Bhatt, S; Devadoss, T; Jindal, A; Mahesh, R | 1 |
| Birmaher, B; Brent, D; Clarke, G; Emslie, GJ; He, J; Hilton, R; Mansoor, B; Mayes, TL; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Cekmen, M; Dursun, M; Kirecci, SL; Otunctemur, A; Ozbek, E; Ozcan, L; Ozdogan, HK | 1 |
| Chen, J; Wang, Y; Wei, Q; Xie, J; Yu, L | 1 |
| Achacoso, N; Friedman, GD; Habel, LA; Kroenke, CH; Meng, MV; Schwalbe, J | 1 |
| Cho, HY; Kim, JE; Kim, YH; Lee, BJ; Lee, CH; Lee, JG; Park, SW; Seo, MK; Seol, W | 1 |
| Seyfried, CA; van Amsterdam, C | 1 |
| Bundeff, AW; Woodis, CB | 1 |
| Degirmencioglu, S; Gurbuz, ZG; Kirecci, SL; Mimaroglu, S; Simsek, A; Vural, P; Yuksel, A | 2 |
| Andrade, C | 1 |
| Sato, Y | 1 |
| Amano, T | 1 |
| Handley, AP; Williams, M | 1 |
| Futuro Neto, HA; Pires, JG; Ramage, AG; Santuzzi, CH; Silva, NF; Tiradentes, RV | 1 |
| Becker, T; Koesters, M; Ma, Y; Zhang, Y | 1 |
| Howard, LM; Karia, AM; McGeown, HR; Molyneaux, E; Trevillion, K | 1 |
| IsHak, WW; Karamians, R; Peselow, ED; Pizano, D; Tobia, G | 1 |
| Hermann, M; Molden, E; Waade, RB | 1 |
| Durairaj, H; Parameswaran, N; Steury, MD | 1 |
| Dueñas, H; Haro, JM; Hong, J; Moneta, MV; Montgomery, W; Novick, D; Peng, X | 1 |
| Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N | 1 |
| Banzi, R; Cusi, C; Moja, L; Randazzo, C; Sterzi, R; Tedesco, D | 1 |
| Cantrell, SE; Häuser, W; Nishishinya, MB; Urrútia, G; Walitt, B | 1 |
| Amodeo, LR; Crawford, CA; Eaton, SE; Greenfield, VY; Harmony, ZR; Humphrey, DE; Johnson, JD; Pipkin, JA; Plant, CP; Varela, V; Wang, L | 1 |
| Halling-Sørensen, B; Hansen, CH; Jacobsen, NW; Nellemann, C; Styrishave, B | 1 |
| Beaulieu, JM; Chahine, M; Poulin, H; Thériault, O | 1 |
| Dao-Ung, P; Fuller, SJ; Skarratt, KK; Stokes, L | 1 |
| Bannink, M; Binkhorst, L; de Bruijn, P; den Boer, TD; Droogendijk, H; Jager, A; Lam, MH; Mathijssen, RH; Ruit, J; van Alphen, RJ; van Gelder, T | 1 |
| Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL | 1 |
| Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A | 1 |
| Bagmetova, VV; Chernysheva, YV; Ozerov, AA; Tyurenkov, IN | 1 |
| Andreão, RV; Benseñor, IM; Bittencourt, MS; Brunoni, AR; Dantas, EM; Fráguas, R; Kemp, AH; Koenig, J; Lotufo, PA; Mill, JG; Nunes, MA; Ribeiro, AL; Thayer, JF | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR | 1 |
| Jiang, CL; Liu, WZ; Shang, ZL; Wang, W; Xiang, ZH | 1 |
| Adamczak, SK; Bury, TBS; Donovan, EE; Fong, PP; Lambert, OJ; Palmucci, JR | 1 |
| Gulbins, E; Kornhuber, J; Kramer, M; Lenz, B; Mühle, C; Reichel, M; Rhein, C; Rotter, A | 1 |
| Bahar, MA; Borgsteede, SD; Bos, JHJ; Hak, E; Wilffert, B | 1 |
| Aksoy, S; Atıcı, M; Erdogan, MS; Ertaş, ET; Isa Kara, M; Kelebek, S; Ozen, E | 1 |
| Casavant, MJ; Chounthirath, T; Russell, JL; Spiller, HA | 1 |
| Jiao, Y; Liang, Y; Lin, J; Qu, H; Sun, Y; Xu, J; Zhao, C | 1 |
| Chen, XF; Gao, NN; Jin, ZL; Li, XR; Li, YF; Ran, YH; Xiong, J; Zheng, YY | 1 |
| Alves, G; Falcão, A; Llerena, A; Magalhães, P | 1 |
| Bartova, L; Dold, M; Kasper, S; Rupprecht, R | 1 |
| Orlando, JM | 1 |
| Farooq, AD; Naqvi, S; Rahman, R; Zeb, F | 1 |
| He, JC; Pu, ZP; Xia, JM; Xie, W | 1 |
| Bahar, MA; Bos, JHJ; Hak, E; Wang, Y; Wilffert, B | 1 |
| Bento, C; Correia, P; Ribeiro, JA; Sales, F | 1 |
| Bogdanova, OV; D'Anci, KE; Kanekar, S; Olson, PR; Ombach, HJ; Petersen, M; Renshaw, CE; Renshaw, PF; Sheth, CS; Sung, YH | 1 |
| Baldwin, DS; Everitt, H; Lipinska, G; Malizia, AL; Manson, CC; Mayers, A; Stuart, B; Wilson, S | 1 |
| Carleton, BC; Etminan, M; Guo, MY; Kezouh, A; Kim, DD; Procyshyn, RM; Samii, A | 1 |
| Bahar, MA; Borgsteede, SD; Hak, E; Kamp, J; Wilffert, B | 1 |
| Gao, YL; He, B | 1 |
| Gui, J; Maguen, S; Schnurr, PP; Shiner, B; Watts, BV; Westgate, CL; Young-Xu, Y | 1 |
| Croarkin, PE; Mills, JA; Strawn, JR | 1 |
| Aitchison, KJ; Binder, EB; Carrillo-Roa, T; Cattaneo, A; DeModena, A; Henigsberg, N; Kelsoe, JR; Leckband, SG; Liu, JJ; McCarthy, M; Mors, O; Ren, H; Rietschel, M; Shekhtman, T; Wei, YB | 1 |
| Blake, CS; Hudd, TR; Nguyen, TT; Rimola-Dejesus, Y; Zaiken, K | 1 |
| Arnold, PD; Bousman, C; Greenslade, A; Maruf, AA | 1 |
| Chen, L; Cheng, S; Guo, S; Xu, H | 1 |
| Brandt, L; Bschor, T; Heinz, A; Henssler, J | 1 |
| Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S | 1 |
| Alsaab, S; Cobb, C; Haidari, M; Mansani, S; Ponds, D; Romero, L | 1 |
| Doucet, N; Hudon Thibeault, AA; López de Los Santos, Y; Sanderson, JT; Vaillancourt, C | 1 |
| Niwa, T; Sugimoto, S | 1 |
| Liao, XM; Si, TM; Su, YA; Wang, Y; Yu, X | 1 |
| Reimers, A; Reis, M; Svensson, M | 1 |
| Baker, A; Bisson, JI; Dekker, W; Hoskins, MD | 1 |
| Airaksinen, J; Elovainio, M; García Velázquez, R; Gluschkoff, K; Jokela, M; Komulainen, K; Savelieva, K | 1 |
| Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L | 1 |
| Cornelius, SL; Gui, J; Hoyt, JE; Leonard, CE; Schnurr, PP; Shiner, B; Watts, BV; Young-Xu, Y | 1 |
| Hui, A | 1 |
| Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM | 1 |
| de Menezes, RT; de Oliveira, HC; de Oliveira, LD; Pereira, TC; Scorzoni, L | 1 |
| Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V | 1 |
| Chen, L; Feng, X; Huang, C; Shen, X; Wang, J; Xu, T | 1 |
| Cui, P; Hao, L; He, X; Jia, Y; Liang, Z; Tong, B; Yang, F; Yuan, J; Zhao, L; Zhu, R | 1 |
| Komarov, SD; Severtsev, VV; Vdovin, AS; Vinnikova, MA | 1 |
| Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC | 1 |
| Bykov, K; Gagne, JJ; Yoshida, K; Yunusa, I | 1 |
| Camino, S; Godoy, A; Smith, J; Strejilevich, SA; Szmulewicz, A | 1 |
| Bracke, F; Frieling, H; Leffler, A | 1 |
| Dunham, KE; Venton, BJ | 1 |
| Dai, Y; Gao, H; Huang, Y; Jiang, H; Liu, Q; Wang, M; Zhang, X | 1 |
| Kenda, M; Sollner Dolenc, M; Zore, T | 1 |
| Al-Khatib, SM; Assimon, MM; Brookhart, MA; Flythe, JE; Gaynes, BN; Pun, PH; Winkelmayer, WC | 1 |
| Gedde-Dahl, A; Molden, E; Spigset, O | 1 |
| Acosta, A; Bielinski, SJ; Camilleri, M; Cifuentes, L; Decker, PA; Gonzalez-Izundegui, D; Hurtado, MD; Moyer, AM; Ricardo-Silgado, ML; Singh, S | 1 |
| Azoulay, L; Cao, TXD; Fergusson, E; Filliter, C; Montastruc, F; Rej, S; Renoux, C; Yu, OHY | 1 |
| Bayati, R; Ghaffari Jolfayi, A; Nakhaee, H; Rahmanian, M; Rakhshanderou, S; Zangiabadian, M | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K | 1 |
| Aljhani, S | 1 |
| Denis, P; Hoertel, N; Lemogne, C; Lesuffleur, T; Limosin, F; Ouazana-Vedrines, C; Rachas, A; Tuppin, P | 1 |
| Amada, N; Futamura, T; Hirose, T; Kakumoto, Y; Kikuchi, T; Maeda, K; Suzuki, M | 1 |
| Alexandre, C; Alexandre, J; Desaunay, P; Dreyfus, M; Eude, LG; Fedrizzi, S; Guénolé, F; Uguz, F | 1 |
| Cao, Q; Rao, Y; Yang, R; Zhao, J | 1 |
| Chen, YM; Guan, W; Huang, J; Jiang, B; Li, WY; Shi, TS; Xu, DW | 1 |
| Barbui, C; Bighelli, I; Caldwell, DM; Cipriani, A; Davies, SJ; Dawson, S; Dias, S; Furukawa, TA; Guaiana, G; Imai, H; Koesters, M; Meader, N; Pompoli, A; Robertson, L; Tajika, A | 1 |
108 review(s) available for paroxetine and fluoxetine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Melancholic/endogenous depression and response to somatic treatment and placebo.
Topics: Antidepressive Agents; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 1992 |
Pharmacokinetics of the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline | 1992 |
The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Topics: 1-Naphthylamine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; In Vitro Techniques; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline | 1992 |
Pharmacotherapy of obsessive compulsive disorder.
Topics: 1-Naphthylamine; Antidepressive Agents; Clomipramine; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Neurotransmitter Uptake Inhibitors; Obsessive-Compulsive Disorder; Paroxetine; Piperidines; Serotonin; Sertraline | 1992 |
5-HT reuptake inhibitors, tricyclic antidepressants and suicidal behaviour.
Topics: Antidepressive Agents; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Mianserin; Paroxetine; Piperidines; Serotonin Antagonists; Suicide; Suicide Prevention | 1991 |
Clinical overview of serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Paroxetine; Piperidines; Serotonin Antagonists; Sertraline; Zimeldine | 1990 |
Depression and selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depression; Fluoxetine; Humans; Imipramine; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Paroxetine; Piperidines; Serotonin Antagonists | 1990 |
Biochemical pharmacology of the serotonin system.
Topics: Alanine; Brain; Citalopram; Clomipramine; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Neurons; Oximes; p-Chloroamphetamine; Paroxetine; Piperidines; Propylamines; Receptors, Serotonin; Reserpine; Serotonin; Serotonin Antagonists; Synapses; Tetrabenazine; Zimeldine | 1986 |
Therapeutic effects of serotonin uptake inhibitors in depression.
Topics: 5-Hydroxytryptophan; Alanine; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Propylamines; Serotonin; Serotonin Antagonists; Trazodone; Zimeldine | 1986 |
Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Topics: 1-Naphthylamine; Animals; Citalopram; Cytochrome P-450 Enzyme System; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Stereoisomerism | 1995 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions.
Topics: 1-Naphthylamine; Alcoholism; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
Pharmacologic treatment of rapid ejaculation.
Topics: 1-Naphthylamine; Adult; Clinical Trials as Topic; Clomipramine; Cyclohexanols; Dose-Response Relationship, Drug; Ejaculation; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Venlafaxine Hydrochloride | 1995 |
Guidelines for the long-term treatment of depression.
Topics: Adult; Amitriptyline; Antidepressive Agents; Clinical Trials as Topic; Combined Modality Therapy; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Follow-Up Studies; Humans; Imipramine; Middle Aged; Paroxetine; Placebos; Psychotherapy; Recurrence; Time Factors; Treatment Outcome | 1994 |
Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Topics: 1-Naphthylamine; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Half-Life; Humans; Metabolic Clearance Rate; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
The pharmacogenetics of the selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents; Citalopram; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Pharmacogenetics; Selective Serotonin Reuptake Inhibitors | 1993 |
Management of recurrent depression.
Topics: 1-Naphthylamine; Antidepressive Agents; Chronic Disease; Combined Modality Therapy; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Imipramine; Paroxetine; Psychotherapy; Recurrence; Sertraline | 1993 |
[New antidepressive agents].
Topics: 1-Naphthylamine; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzamides; Child; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Moclobemide; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1995 |
Use of serotonin selective reuptake inhibitors in geriatric depression.
Topics: 1-Naphthylamine; Age Factors; Aged; Controlled Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Antidepressants in the treatment of premature ejaculation.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Clomipramine; Combined Modality Therapy; Ejaculation; Fluoxetine; Humans; Male; Paroxetine; Psychotherapy; Sertraline; Sexual Dysfunctions, Psychological | 1996 |
Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Female; Fluoxetine; Fluvoxamine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Paroxetine; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I.
Topics: Cytochrome P-450 CYP1A1; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Isoenzymes; Microsomes, Liver; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Depression: making the diagnosis and using SSRIs in the older patient.
Topics: 1-Naphthylamine; Adult; Aged; Alzheimer Disease; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Costs and Cost Analysis; Dopamine Antagonists; Drug Interactions; Drug Tolerance; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Lithium; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Tryptophan | 1996 |
Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Topics: 1-Naphthylamine; Animals; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Fluoxetine; Fluvoxamine; Humans; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Movement disorders associated with the serotonin selective reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Age Factors; Aged; Akathisia, Drug-Induced; Depressive Disorder; Dyskinesia, Drug-Induced; Dystonia; Female; Fluoxetine; Fluvoxamine; Humans; Male; MEDLINE; Middle Aged; Parkinson Disease, Secondary; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; United States | 1996 |
The role of SSRIs in panic disorder.
Topics: 1-Naphthylamine; Citalopram; Clinical Trials as Topic; Clomipramine; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients.
Topics: 1-Naphthylamine; Chromatography; Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Antidepressant discontinuation: a review of the literature.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressive Disorder; Fluoxetine; Humans; Incidence; Monoamine Oxidase Inhibitors; Paroxetine; Recurrence; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Newer antidepressants and the discontinuation syndrome.
Topics: Adverse Drug Reaction Reporting Systems; Cyclohexanols; Dizziness; Fluoxetine; Headache; Humans; Incidence; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Stages; Substance Withdrawal Syndrome; Syndrome; Venlafaxine Hydrochloride | 1997 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Female; Fluoxetine; Fluvoxamine; Headache; Humans; Infant; Infant, Newborn; Male; MEDLINE; Mental Disorders; Middle Aged; Nausea; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensation Disorders; Sertraline; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome; Venlafaxine Hydrochloride | 1997 |
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 1997 |
Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Topics: 1-Naphthylamine; Antidepressive Agents; Cyclohexanols; Cytochrome P-450 Enzyme System; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1997 |
The use of newer antidepressants for panic disorder.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 1997 |
Antidepressant response in late-life depression.
Topics: 1-Naphthylamine; Age Factors; Aged; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Middle Aged; Nortriptyline; Paroxetine; Patient Dropouts; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1998 |
SSRI safety in overdose.
Topics: Adult; Child; Citalopram; Drug Overdose; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Poison Control Centers; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1998 |
Mirtazapine versus selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Citalopram; Clinical Trials as Topic; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone.
Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Binding, Competitive; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Fluoxetine; Humans; Hydrocodone; Oxycodone; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors | 1998 |
Current concepts in the treatment of panic disorder.
Topics: Antidepressive Agents, Tricyclic; Benzodiazepines; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Monoamine Oxidase Inhibitors; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
Pharmacological treatment of premature ejaculation.
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Ejaculation; Fluoxetine; Humans; Male; Paroxetine; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Sexual Dysfunction, Physiological | 1999 |
Pharmacokinetics of selective serotonin reuptake inhibitors.
Topics: Citalopram; Clinical Trials as Topic; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2000 |
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Fluoxetine; Follow-Up Studies; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 2000 |
Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors.
Topics: Anti-Bacterial Agents; Bacteria; Corynebacterium; Drug Synergism; Fluoxetine; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2000 |
Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Topics: Animals; Brain; Cerebrovascular Circulation; Clinical Trials as Topic; Depressive Disorder, Major; Drug Synergism; Fluoxetine; Humans; Paroxetine; Pindolol; Rats; Selective Serotonin Reuptake Inhibitors; Tomography, Emission-Computed | 2000 |
Psychopharmacologic treatment of adolescent depression.
Topics: Adolescent; Child; Cyclohexanols; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2001 |
Venlafaxine extended-release: a review of its use in the management of major depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2001 |
Obsessive-compulsive disorder: identification, neurobiology, and treatment.
Topics: Adult; Behavior Therapy; Child; Combined Modality Therapy; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2002 |
Serotonin agents in the treatment of acquired brain injury.
Topics: Brain Injuries; Citalopram; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Injury Severity Score; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2002 |
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride | 2002 |
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Dementia; Depression; Fluoxetine; Humans; Neuropsychological Tests; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Time Factors; Trazodone | 2003 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Behavior Therapy; Child; Citalopram; Clomipramine; Depression; Diagnosis, Differential; Eczema; Family Practice; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychotherapy; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Surveys and Questionnaires; Time Factors; Trichotillomania | 2003 |
A hot flash on tamoxifen metabolism.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cyclohexanols; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Fluoxetine; Hot Flashes; Humans; Hydroxylation; Paroxetine; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Venlafaxine Hydrochloride | 2003 |
Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Topics: Autistic Disorder; Citalopram; Clinical Trials as Topic; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Fluoxetine; Fluvoxamine; Humans; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
Noradrenergic and serotonergic modulation to treat vasomotor symptoms.
Topics: Citalopram; Cyclohexanols; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Mianserin; Mirtazapine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Trazodone; Venlafaxine Hydrochloride | 2006 |
Antidepressants and risk of upper gastrointestinal bleeding.
Topics: Adverse Drug Reaction Reporting Systems; Age Factors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Blood Platelets; Drug Interactions; Epidemiologic Studies; Fluoxetine; Gastrointestinal Hemorrhage; Humans; Paroxetine; Platelet Aggregation; Risk Factors; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Upper Gastrointestinal Tract | 2006 |
Did regulators fail over selective serotonin reuptake inhibitors?
Topics: Antidepressive Agents, Second-Generation; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Drug Approval; Fluoxetine; Humans; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Suicide; United States; United States Food and Drug Administration | 2006 |
Pharmacotherapy of child and adolescent depression.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Sertraline; Social Behavior | 2006 |
Pharmacotherapy of aphasia: myth or reality?
Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Fluoxetine; GABA Agonists; Humans; Indans; Neuroprotective Agents; Paroxetine; Physostigmine; Piperidines; Piracetam; Pyridines; Selective Serotonin Reuptake Inhibitors; Serotonin; Stroke; Zolpidem | 2007 |
[Safety of selective serotonin reuptake inhibitor antidepressants in children and adolescents].
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents, Second-Generation; Case-Control Studies; Child, Preschool; Citalopram; Confidence Intervals; Depressive Disorder; Family Practice; Female; Fluoxetine; Fluvoxamine; History, Medieval; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Placebos; Psychotherapy; Randomized Controlled Trials as Topic; Risk; Safety; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Suicide; Suicide, Attempted | 2006 |
Treating vasomotor symptoms of menopause: the nurse practitioner's perspective.
Topics: Adrenergic alpha-Agonists; Algorithms; Amines; Citalopram; Clonidine; Complementary Therapies; Cyclohexanecarboxylic Acids; Estrogen Replacement Therapy; Evidence-Based Medicine; Female; Fluoxetine; Gabapentin; gamma-Aminobutyric Acid; Hot Flashes; Humans; Life Style; Menopause; Middle Aged; Nurse Practitioners; Paroxetine; Patient Education as Topic; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Safety Management; Selective Serotonin Reuptake Inhibitors | 2007 |
Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide | 2007 |
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2008 |
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2007 |
Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Topics: Adult; Citalopram; Female; Fluoxetine; Fluvoxamine; Humans; Odds Ratio; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2008 |
Antidepressant medication use during breastfeeding.
Topics: Antidepressive Agents, Second-Generation; Breast Feeding; Citalopram; Depression, Postpartum; Female; Fluoxetine; Humans; Infant; Lactation; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline | 2009 |
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1999 |
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).
Topics: Adult; Breast Feeding; Cardiovascular Abnormalities; Congenital Abnormalities; Female; Fluoxetine; Humans; Hypertension, Pulmonary; Infant, Newborn; Lactation; Maternal Exposure; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; PubMed; Respiratory Distress Syndrome, Newborn; Risk Assessment; Selective Serotonin Reuptake Inhibitors | 2010 |
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2010 |
Selective serotonin-reuptake inhibitors in the treatment of panic disorder: a systematic review of placebo-controlled studies.
Topics: Citalopram; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Panic Disorder; Paroxetine; Placebo Effect; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update.
Topics: Abnormalities, Drug-Induced; Cardiovascular Abnormalities; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Humans; Maternal-Fetal Exchange; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Teratogens | 2010 |
[Selective serotonin reuptake inhibitors and mammary pathologies].
Topics: Antidepressive Agents; Breast Neoplasms; Citalopram; Clinical Trials as Topic; Female; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
[Interactions between metoprolol and antidepressants].
Topics: Adrenergic beta-1 Receptor Antagonists; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Metoprolol; Paroxetine; Risk Factors | 2011 |
Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.
Topics: Benzofurans; Citalopram; Depressive Disorder; Drug Monitoring; Fluoxetine; Fluvoxamine; Humans; Indoles; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Vilazodone Hydrochloride | 2012 |
Duloxetine versus other anti-depressive agents for depression.
Topics: Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Desvenlafaxine Succinate; Dibenzothiazepines; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Newer generation antidepressants for depressive disorders in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder; Fluoxetine; Humans; Induction Chemotherapy; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide | 2012 |
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
Topics: Adult; Anxiety; Citalopram; Cognition; Depression; Fluoxetine; Humans; Nervous System Diseases; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Stroke; Stroke Rehabilitation | 2012 |
Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2014 |
Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome.
Topics: Citalopram; Fluoxetine; Humans; Irritable Bowel Syndrome; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors | 2014 |
The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review.
Topics: Adult; Aged; Citalopram; Desvenlafaxine Succinate; Female; Fluoxetine; Hot Flashes; Humans; Menopause; Middle Aged; Paroxetine; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Vasomotor System; Venlafaxine Hydrochloride | 2015 |
A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; China; Citalopram; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2014 |
Antidepressant treatment for postnatal depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depression, Postpartum; Female; Fluoxetine; Humans; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2014 |
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Topics: Adrenergic Uptake Inhibitors; Adult; Citalopram; Cyclohexanols; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Tension-Type Headache; Venlafaxine Hydrochloride | 2015 |
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
Topics: Amitriptyline; Citalopram; Fibromyalgia; Fluoxetine; Humans; Melatonin; Musculoskeletal Pain; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Syndrome | 2015 |
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2016 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Pharmacogenetics; Practice Guidelines as Topic; Precision Medicine; Prescription Drugs; Venlafaxine Hydrochloride | 2016 |
Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2017 |
Antidepressants for insomnia in adults.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Fluoxetine; Humans; Mianserin; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Trazodone | 2018 |
The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.
Topics: Cytochrome P-450 CYP2D6; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Paroxetine | 2018 |
Antidepressant pharmacogenetics in children and young adults: A systematic review.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mental Disorders; Nortriptyline; Paroxetine; Pharmacogenetics; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tryptophan Hydroxylase; Venlafaxine Hydrochloride; Young Adult | 2019 |
Comparative cardiovascular safety of selective serotonin reuptake inhibitors (SSRIs) among Chinese senile depression patients: A network meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Asian People; Cardiovascular Diseases; China; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2019 |
Antidepressant Withdrawal and Rebound Phenomena.
Topics: Antidepressive Agents; Fluoxetine; Humans; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2019 |
In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis.
Topics: Depression; Dose-Response Relationship, Drug; Fluoxetine; Humans; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2020 |
Exploring the utility of RDoC in differentiating effectiveness amongst antidepressants: A systematic review using proposed psychometrics as the unit of analysis for the Negative Valence Systems domain.
Topics: Algorithms; Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depressive Disorder; Desvenlafaxine Succinate; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Psychometrics; Sertraline; Treatment Outcome | 2020 |
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine | 2021 |
Recent sample pretreatment methods for determination of selective serotonin reuptake inhibitors (SSRIs) in biological samples.
Topics: Citalopram; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
Are all antidepressants the same? The consumer has a point.
Topics: Antidepressive Agents; Bupropion; Citalopram; Fluoxetine; Humans; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2023 |
Comparison of fluoxetine with other selective serotonin reuptake inhibitors in the treatment of premature ejaculation: A systematic review and meta-analysis.
Topics: Ejaculation; Fluoxetine; Humans; Male; Paroxetine; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2022 |
The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A systematic review and meta-analysis.
Topics: Antidepressive Agents; COVID-19 Drug Treatment; Fluoxetine; Fluvoxamine; Humans; Norepinephrine; Paroxetine; SARS-CoV-2; Selective Serotonin Reuptake Inhibitors; Serotonin; Venlafaxine Hydrochloride | 2022 |
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine | 2023 |
Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses.
Topics: Antidepressive Agents; Child; Female; Fluoxetine; Humans; Infant, Newborn; Paroxetine; Pregnancy; Premature Birth; Risk Assessment; Sertraline | 2023 |
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride | 2022 |
Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Topics: Adult; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Clomipramine; Clonazepam; Desipramine; Diazepam; Fluoxetine; Humans; Network Meta-Analysis; Panic Disorder; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride | 2023 |
97 trial(s) available for paroxetine and fluoxetine
| Article | Year |
|---|---|
Sociotropy and autonomy: relationship to antidepressant drug treatment response and endogenous-nonendogenous dichotomy.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Individuality; Internal-External Control; Interpersonal Relations; Male; Oximes; Paroxetine; Piperidines; Serotonin Antagonists | 1992 |
Melancholic/endogenous depression and response to somatic treatment and placebo.
Topics: Antidepressive Agents; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Imipramine; Oximes; Paroxetine; Piperidines; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome | 1992 |
Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities.
Topics: Adult; Arousal; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Monitoring, Physiologic; Paroxetine; Piperidines; Serotonin Antagonists; Sleep Stages; Wakefulness | 1991 |
Clinical trials of antidepressants: the hidden face: where locus of control appears to play a key role in depression outcome.
Topics: Adult; Antidepressive Agents; Depression; Fluoxetine; Humans; Internal-External Control; Maprotiline; Paroxetine; Psychiatric Status Rating Scales; Time Factors; Treatment Outcome | 1995 |
Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological | 1995 |
A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Half-Life; Humans; Incidence; Male; Paroxetine; Placebos; Substance Withdrawal Syndrome; Time Factors | 1995 |
Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study.
Topics: Adolescent; Adult; Agoraphobia; Female; Fluoxetine; Humans; Imipramine; Male; Middle Aged; Panic Disorder; Paroxetine; Patient Dropouts; Prospective Studies; Psychiatric Status Rating Scales | 1995 |
Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine.
Topics: Adolescent; Adult; Aged; Blood Platelets; Cell Membrane; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Lofepramine; Male; Middle Aged; Paroxetine; Receptors, Serotonin | 1994 |
[Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine].
Topics: Aged; Aged, 80 and over; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales | 1994 |
Childhood psychopathology retrospectively assessed among adults with early onset major depression.
Topics: 1-Naphthylamine; Adolescent; Adult; Anxiety Disorders; Child; Child Behavior Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imipramine; Male; Mental Disorders; Middle Aged; Paroxetine; Personality Development; Phobic Disorders; Recurrence; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1994 |
A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression.
Topics: Adolescent; Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; France; Hospitalization; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Treatment Outcome | 1993 |
A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression.
Topics: Aged; Aged, 80 and over; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Geriatric Assessment; Humans; Male; Mental Status Schedule; Middle Aged; Paroxetine; Personality Inventory; Treatment Outcome | 1993 |
Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Geriatric Assessment; Humans; Male; Middle Aged; Neuropsychological Tests; Paroxetine; Personality Inventory; Social Behavior; Treatment Outcome | 1994 |
Response to SSRI antidepressants correlates with reduction in plasma HVA: pilot study.
Topics: Adult; Aged; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Homovanillic Acid; Humans; Hydrocortisone; Male; Middle Aged; Paroxetine; Personality Inventory; Pilot Projects; Prolactin; Treatment Outcome | 1993 |
Platelet paroxetine binding and fluoxetine pharmacotherapy in posttraumatic stress disorder: preliminary observations on a possible predictor of clinical treatment response.
Topics: Adult; Blood Platelets; Drug Interactions; Fluoxetine; Humans; Kinetics; Male; Middle Aged; Paroxetine; Stress Disorders, Post-Traumatic; Tritium | 1994 |
A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
Topics: Adolescent; Adult; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Nausea; Paroxetine; Vomiting | 1993 |
Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series.
Topics: Adult; Aged; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Methylphenidate; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 1996 |
Response to an open trial of a second SSRI in major depression.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1996 |
Lack of change in fluoxetine and norfluoxetine kinetics when switching from fluoxetine to paroxetine.
Topics: Adult; Aged; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Caffeine; Chromatography, High Pressure Liquid; Citalopram; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sparteine | 1996 |
Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Topics: Adult; Benzamides; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Headache; Humans; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Nausea; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders | 1996 |
Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder.
Topics: Adult; Blood Platelets; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Lysergic Acid Diethylamide; Male; Middle Aged; Paroxetine; Personality Inventory; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin | 1997 |
An open-label study of SSRI treatment in depressed hispanic and non-Hispanic women.
Topics: Adult; Depressive Disorder; Female; Fluoxetine; Hispanic or Latino; Humans; Middle Aged; Paroxetine; Prospective Studies; Treatment Outcome | 1997 |
Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms.
Topics: 1-Naphthylamine; Acquired Immunodeficiency Syndrome; Adaptation, Psychological; Adult; Depressive Disorder; Female; Fluoxetine; HIV Infections; Humans; Male; Middle Aged; Paroxetine; Patient Care Team; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Sertraline; Sick Role; Somatoform Disorders | 1997 |
Personality disorder scores improve with effective pharmacotherapy of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Ergolines; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Disorders; Personality Inventory; Serotonin Antagonists | 1997 |
Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Compulsive Behavior; Dementia; Depressive Disorder; Female; Fluoxetine; Frontal Lobe; Humans; Impulsive Behavior; Male; Middle Aged; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Temporal Lobe; Treatment Outcome | 1997 |
Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatrically hospitalized adolescents: results of an open trial.
Topics: 1-Naphthylamine; Adolescent; Aggression; Female; Fluoxetine; Humans; Inpatients; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Sexual Dysfunctions, Psychological; Surveys and Questionnaires | 1997 |
Antidepressant response follows an exponential decay curve: replication and extension.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Imipramine; Models, Statistical; Paroxetine; Personality Inventory; Psychometrics; Pyridazines; Treatment Outcome | 1997 |
Use of SSRIs in "very old" depressed nursing home residents.
Topics: 1-Naphthylamine; Aged; Aged, 80 and over; Alzheimer Disease; Central Nervous System Diseases; Dementia, Vascular; Depressive Disorder; Female; Fluoxetine; Homes for the Aged; Humans; Male; Matched-Pair Analysis; New York; Nursing Homes; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Statistics, Nonparametric | 1998 |
Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders.
Topics: 1-Naphthylamine; Adult; Anxiety; Ejaculation; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; Orgasm; Paroxetine; Penile Erection; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunction, Physiological | 1998 |
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Topics: 1-Naphthylamine; Adult; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Half-Life; Health Status; Humans; Male; Middle Aged; Paroxetine; Placebos; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Substance Withdrawal Syndrome; Surveys and Questionnaires | 1998 |
Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Double-Blind Method; Ejaculation; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Reaction Time; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Antidepressants augment natural killer cell activity: in vivo and in vitro.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Humans; Immunoassay; In Vitro Techniques; Killer Cells, Natural; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Stimulation, Chemical | 1999 |
A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
Topics: Adult; Ambulatory Care; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Gastrointestinal Diseases; Humans; Male; Paroxetine; Patient Dropouts; Placebos; Psychiatric Status Rating Scales; Sexual Dysfunctions, Psychological; Treatment Outcome | 1998 |
A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius.
Topics: Adult; Ambulatory Care; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Pindolol; Placebos; Selective Serotonin Reuptake Inhibitors; Single-Blind Method | 1999 |
CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
Topics: Adult; Cytochrome P-450 CYP2D6; Dextromethorphan; Dextrorphan; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Reference Values; Sertraline | 1999 |
Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.
Topics: Adult; Aged; Ambulatory Care; Antipsychotic Agents; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Treatment Outcome | 1999 |
Relief of SSRI-induced sexual dysfunction with mirtazapine treatment.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Therapy, Combination; Female; Fluoxetine; Humans; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sexual Dysfunctions, Psychological; Treatment Outcome | 1999 |
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
Topics: Adult; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 1999 |
Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Anxiety Disorders; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Medical Records; Mental Disorders; Middle Aged; Mood Disorders; Paroxetine; Retrospective Studies; Sampling Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
Topics: Chromatography, High Pressure Liquid; Cross-Over Studies; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Humans; Isoenzymes; Paroxetine; Phenotype; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment.
Topics: Adult; Biomarkers; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Hemodynamics; Hormones; Humans; Male; Paroxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress, Psychological; Substance Withdrawal Syndrome | 2000 |
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Female; Fluoxetine; Humans; Immune Tolerance; Lymphocyte Activation; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Venlafaxine Hydrochloride | 2000 |
Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.
Topics: Adult; Analysis of Variance; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mental Disorders; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2000 |
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2000 |
Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study.
Topics: Adult; Brain; Brain Chemistry; Depressive Disorder; Double-Blind Method; Female; Fluorine; Fluoxetine; Humans; Magnetic Resonance Spectroscopy; Male; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors | 2000 |
Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.
Topics: Adult; Antidepressive Agents; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Libido; Male; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Surveys and Questionnaires; Time Factors | 2000 |
Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Longitudinal Studies; Male; Middle Aged; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2000 |
Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder.
Topics: Adult; Ambulatory Care; Depression; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Stress Disorders, Post-Traumatic; Treatment Outcome; Triiodothyronine | 2001 |
Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2001 |
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Paroxetine; Personality Inventory; Sertraline; Sleep Initiation and Maintenance Disorders; Treatment Outcome | 2002 |
Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6 Inhibitors; Female; Fluoxetine; Half-Life; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 2002 |
Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus.
Topics: Aged; Female; Fluoxetine; Humans; Male; Paroxetine; Polycythemia Vera; Pruritus; Recurrence; Selective Serotonin Reuptake Inhibitors | 2002 |
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Dopamine Uptake Inhibitors; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Surveys and Questionnaires; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States | 2002 |
Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Dysthymic Disorder; Female; Fluoxetine; Humans; Interview, Psychological; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Time Factors | 2002 |
Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
Topics: Affect; Age Factors; Aged; Ambulatory Care; Anxiety Disorders; Cognition; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Survival Analysis; Treatment Outcome | 2002 |
CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Topics: Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dextromethorphan; Dextrorphan; Fluoxetine; Fluvoxamine; Genotype; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Social Behavior; Substance Withdrawal Syndrome | 2002 |
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.
Topics: Antipsychotic Agents; Benzodiazepines; Combat Disorders; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; Male; Middle Aged; Olanzapine; Paroxetine; Pirenzepine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Sleep Wake Disorders; Treatment Outcome | 2002 |
Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
Topics: Aged; Aged, 80 and over; Cytochrome P-450 CYP2D6; Depressive Disorder; Female; Fluoxetine; Genotype; Humans; Hyponatremia; Male; Middle Aged; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors | 2002 |
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment.
Topics: Adult; Caudate Nucleus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Paroxetine; Prefrontal Cortex; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires | 2003 |
[3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine.
Topics: Adult; Cell Membrane; Depressive Disorder; Female; Fluoxetine; Humans; Hydroxyindoleacetic Acid; Lymphocytes; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin | 1999 |
Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
Topics: Adult; Aged; Algorithms; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluoxetine; Humans; Male; Middle Aged; Outpatients; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Triiodothyronine | 2003 |
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
Topics: Adult; Brain Mapping; Choline; Depressive Disorder, Major; Female; Fluoxetine; Gyrus Cinguli; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Spectroscopy; Paroxetine; Phosphocreatine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Syndrome | 2003 |
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Connecticut; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Hospitals, Veterans; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Pindolol; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Veterans | 2004 |
Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants.
Topics: Cognitive Behavioral Therapy; Cross-Over Studies; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tryptophan | 2004 |
The outcome of physical symptoms with treatment of depression.
Topics: Depressive Disorder; Female; Fluoxetine; Follow-Up Studies; Health Status; Health Surveys; Humans; Male; Middle Aged; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Somatoform Disorders; Treatment Outcome | 2004 |
Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
Topics: Adult; Analysis of Variance; Brain Mapping; Cocaine; Depressive Disorder, Major; Diencephalon; Female; Fluoxetine; Humans; Iodine Radioisotopes; Male; Matched-Pair Analysis; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Radiopharmaceuticals; Reference Values; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2004 |
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Male; Obesity; Obsessive-Compulsive Disorder; Paroxetine; Patient Compliance; Prospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2004 |
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Europe; Female; Fluoxetine; Humans; Male; Middle Aged; Nausea; Paroxetine; Prevalence; Severity of Illness Index; Sex Factors; Thiophenes; Time Factors; United States | 2004 |
Dopaminergic mechanism of antidepressant action in depressed patients.
Topics: Adult; Affect; Case-Control Studies; Citalopram; Depressive Disorder, Major; Dopamine Antagonists; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Activity; Paroxetine; Receptors, Dopamine D2; Receptors, Dopamine D3; Selective Serotonin Reuptake Inhibitors; Sulpiride; Treatment Outcome | 2005 |
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Placebos; Treatment Outcome; Venlafaxine Hydrochloride | 2005 |
Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects.
Topics: Acoustic Impedance Tests; Adult; Brain; Depression; Dichotic Listening Tests; Evoked Potentials, Auditory, Brain Stem; Female; Fluoxetine; Humans; Loudness Perception; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Speech Perception | 2005 |
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-12; Male; Middle Aged; Paroxetine; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |
Phenytoin as an augmentation for SSRI failures: a small controlled study.
Topics: Adult; Aged; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Phenytoin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2006 |
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome | 2006 |
[Clinical observation on treatment of melancholia by acupuncture following principle of relieving depression and regulating mentality].
Topics: Acupuncture Therapy; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Electroacupuncture; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Treatment Outcome | 2007 |
An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Bupropion; Dizziness; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Headache; Humans; Male; Middle Aged; Nausea; Paroxetine; Pilot Projects; Piperazines; Quality of Life; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tension-type headache.
Topics: Adult; Character; Chronic Disease; Citalopram; Female; Fluoxetine; Harm Reduction; Humans; Internal-External Control; Male; Paroxetine; Personal Autonomy; Personality Inventory; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Temperament; Tension-Type Headache | 2007 |
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome | 2007 |
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Personality Inventory; Prognosis; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2009 |
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Effects of SNS activation on SSRI-induced sexual side effects differ by SSRI.
Topics: Adrenergic Agents; Adult; Arousal; Cross-Over Studies; Depressive Disorder; Double-Blind Method; Ephedrine; Female; Fluoxetine; Humans; Norepinephrine; Orgasm; Paroxetine; Premedication; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Sexual Behavior; Sexual Dysfunction, Physiological; Sympathetic Nervous System | 2009 |
Depression and comorbid panic in primary care patients.
Topics: Adult; Comorbidity; Depressive Disorder; Female; Fluoxetine; Humans; Longitudinal Studies; Male; Middle Aged; Multicenter Studies as Topic; Panic Disorder; Paroxetine; Primary Health Care; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States | 2010 |
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sleep Wake Disorders; Trazodone; Treatment Outcome; Venlafaxine Hydrochloride | 2012 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation.
Topics: Adult; Case-Control Studies; Female; Fluoxetine; Humans; Male; Middle Aged; Nitric Oxide; Paroxetine; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2014 |
Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation.
Topics: Adult; Fluoxetine; Humans; Male; Melatonin; Middle Aged; Paroxetine; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult | 2014 |
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
Topics: Adult; Antidepressive Agents; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Female; Fluoxetine; Genotype; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen; Venlafaxine Hydrochloride | 2016 |
Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Paroxetine; Prospective Studies | 2021 |
Agomelatine might be more appropriate for elderly, depressed, type 2 diabetes mellitus patients than paroxetine/fluoxetine.
Topics: Acetamides; Adult; Aged; Aging; Antidepressive Agents, Second-Generation; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine | 2021 |
[Fluvoxamine in the treatment of depressive disorders in alcohol dependence: results of randomized open-label comparative study].
Topics: Alcoholism; Citalopram; Depressive Disorder; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2021 |
382 other study(ies) available for paroxetine and fluoxetine
| Article | Year |
|---|---|
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
Topics: Animals; Antidepressive Agents; Biological Assay; Biological Transport; Dose-Response Relationship, Drug; Isoquinolines; Mice; Pyrroles; Rats; Serotonin; Structure-Activity Relationship | 1990 |
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
Topics: Antidepressive Agents; Brain; Carrier Proteins; Cell Line; Dopamine Plasma Membrane Transport Proteins; Humans; In Vitro Techniques; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Protein Binding; Radioligand Assay; Serotonin Plasma Membrane Transport Proteins; Symporters; Synaptosomes | 1997 |
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
Topics: Amino Alcohols; Animals; Antidepressive Agents; Dopamine; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Serotonin; Species Specificity | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1.
Topics: Animals; Binding, Competitive; Carrier Proteins; Cell Membrane; Cerebral Cortex; Citalopram; Drug Design; Indicators and Reagents; Kinetics; Membrane Glycoproteins; Membrane Transport Proteins; Models, Structural; Molecular Conformation; Nerve Tissue Proteins; Quipazine; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2000 |
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Carrier Proteins; Colony-Forming Units Assay; Conditioning, Operant; Cyclic AMP; HeLa Cells; Humans; Hypothermia; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Nerve Tissue Proteins; Piperazines; Radioligand Assay; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Thiophenes | 2001 |
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines.
Topics: Animals; Binding, Competitive; Carrier Proteins; Cerebral Cortex; Citalopram; Drug Design; Fluoxetine; Inhibitory Concentration 50; Kinetics; Male; Membrane Glycoproteins; Membrane Transport Proteins; Models, Structural; Nerve Tissue Proteins; Paroxetine; Quipazine; Rats; Rats, Sprague-Dawley; Serotonin Antagonists; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2002 |
Inhibition of P-glycoprotein by newer antidepressants.
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection | 2003 |
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters | 2003 |
Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
Topics: Animals; Crystallography, X-Ray; Cyclopropanes; Frontal Lobe; Humans; Indoles; Microdialysis; Models, Molecular; Molecular Conformation; Radioligand Assay; Rats; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Stereoisomerism; Structure-Activity Relationship; Tryptamines | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
Topics: Aging; Animals; Antidepressive Agents; Caenorhabditis elegans; Caloric Restriction; Humans; Longevity; Methiothepin; Mianserin; Octopamine; Receptors, Biogenic Amine; Receptors, Serotonin, 5-HT4; Serotonin; Serotonin 5-HT4 Receptor Antagonists; Serotonin Antagonists; Signal Transduction; Starvation | 2007 |
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
Topics: Humans; Indoles; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
Topics: Animals; Antidepressive Agents; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Mice; Motor Activity; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
Topics: Antidepressive Agents; Astrocytes; Cell Line; HEK293 Cells; Humans; Neurokinin-1 Receptor Antagonists; Piperidines; Receptors, Neurokinin-1; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Ligands; Models, Molecular; Molecular Structure; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship | 2021 |
Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: different effects of clomipramine and fluoxetine.
Topics: Animals; Biological Transport, Active; Blood Platelets; Clomipramine; Endothelium, Vascular; Fluoxetine; Lung; Male; Paroxetine; Piperidines; Plasma; Rats; Rats, Inbred Strains; Serotonin | 1992 |
The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sparteine | 1992 |
[3H] sertraline binding to rat brain membranes.
Topics: 1-Naphthylamine; Animals; Brain; Fenclonine; Fluoxetine; Imipramine; In Vitro Techniques; Male; Membranes; Naphthalenes; Paroxetine; Piperidines; Rats; Receptors, Serotonin; Serotonin Antagonists; Sertraline | 1990 |
Interaction of fluoxetine with the human placental serotonin transporter.
Topics: Carrier Proteins; Female; Fluoxetine; Humans; In Vitro Techniques; Microvilli; Paroxetine; Piperidines; Placenta; Pregnancy; Serotonin; Serotonin Antagonists | 1990 |
A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Binding Sites; Binding, Competitive; Biological Transport; Cerebral Cortex; Citalopram; Dose-Response Relationship, Drug; Ethylmaleimide; Fluoxetine; Imipramine; Male; Neurons; Paroxetine; Piperidines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Sodium | 1989 |
The stereoselectivity of serotonin uptake in brain tissue and blood platelets: the topography of the serotonin uptake area.
Topics: Alanine; Amphetamine; Aniline Compounds; Animals; Antidepressive Agents; Blood Platelets; Brain; Fluoxetine; Humans; Male; Methadone; Mianserin; Mirtazapine; Morpholines; Naphthalenes; Nefopam; Nomifensine; Paroxetine; Piperidines; Rabbits; Serotonin; Stereoisomerism; Tranylcypromine; Viloxazine; Zimeldine | 1986 |
Characterization of [3H]paroxetine binding in rat brain.
Topics: Animals; Binding, Competitive; Brain; Cell Membrane; Cerebral Cortex; Citalopram; Fluoxetine; Imipramine; Male; Paroxetine; Peptide Hydrolases; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists; Tritium | 1988 |
Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Autoradiography; Brain Stem; Electrophysiology; Fluoxetine; In Vitro Techniques; Male; Neurons; Paroxetine; Piperazines; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1995 |
The effects of GR127935, a putative 5-HT1D receptor antagonist, on brain 5-HT metabolism, extracellular 5-HT concentration and behaviour in the guinea pig.
Topics: Animals; Biogenic Monoamines; Brain; Dyskinesia, Drug-Induced; Electric Stimulation; Fluoxetine; Guinea Pigs; Humans; In Vitro Techniques; Male; Methiothepin; Oxadiazoles; Paroxetine; Piperazines; Raphe Nuclei; Serotonin Antagonists; Synaptic Transmission; Tryptophan | 1995 |
Changes in paroxetine binding in the cerebral cortex of polydipsic rats.
Topics: Animals; Binding, Competitive; Cerebral Cortex; Disease Models, Animal; Drinking Behavior; Fluoxetine; Food Deprivation; Isotope Labeling; Obsessive-Compulsive Disorder; Paroxetine; Random Allocation; Rats; Thirst; Tritium | 1995 |
The effects of single and repeated anorectic doses of 5-hydroxytryptamine uptake inhibitors on indole levels in rat brain.
Topics: 1-Naphthylamine; Animals; Appetite Depressants; Brain Chemistry; Eating; Fluoxetine; Fluvoxamine; Hydroxyindoleacetic Acid; Indoles; Male; Paroxetine; Rats; Rats, Inbred Strains; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline | 1993 |
Isolation-induced aggression in mice: effects of 5-hydroxytryptamine uptake inhibitors and involvement of postsynaptic 5-HT1A receptors.
Topics: 1-Naphthylamine; 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Analysis of Variance; Animals; Behavior, Animal; Brain; Citalopram; Dose-Response Relationship, Drug; Fenclonine; Fluoxetine; Fluvoxamine; Male; Mice; Paroxetine; Penbutolol; Piperidines; Rats; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Sertraline; Synaptosomes | 1994 |
[Fluoxetine in perspective].
Topics: Amitriptyline; Depression; Double-Blind Method; Fluoxetine; Humans; Paroxetine | 1994 |
Serotonin reuptake inhibitors in Raynaud's phenomenon.
Topics: 1-Naphthylamine; Adult; Aged; Cyclohexanols; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Raynaud Disease; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 1995 |
Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C/2B receptor function.
Topics: Animals; Brain; Clomipramine; Desipramine; Fluoxetine; Male; Motor Activity; Norepinephrine; Paroxetine; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Time Factors | 1994 |
Serotonin uptake inhibitors modulate intracellular Ca2+ mobilization in platelets.
Topics: 1-Naphthylamine; Blood Platelets; Calcium; Calmodulin; Cells, Cultured; Fluoxetine; Humans; Imipramine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1995 |
Treatment of drug-induced anorgasmia.
Topics: Female; Fluoxetine; Humans; Male; Orgasm; Paroxetine; Sexual Dysfunctions, Psychological; Yohimbine | 1994 |
Binding of bromine-substituted analogs of methylphenidate to monoamine transporters.
Topics: Animals; Binding, Competitive; Bromine; Carrier Proteins; Chromatography, High Pressure Liquid; Cocaine; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Mice; Microdialysis; Motor Activity; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Tomography, Emission-Computed, Single-Photon | 1994 |
Valproate pretreatment for the difficult-to-treat patient with OCD.
Topics: 1-Naphthylamine; Antidepressive Agents; Clomipramine; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Sertraline; Treatment Outcome; Valproic Acid | 1994 |
Comparison of stimulus properties of fluoxetine and 5-HT receptor agonists in a conditioned taste aversion procedure.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Amphetamines; Analysis of Variance; Animals; Avoidance Learning; Conditioning, Classical; Fluoxetine; Male; Mice; Paroxetine; Pyrazines; Serotonin Receptor Agonists; Taste | 1994 |
Platelet 3H-paroxetine binding in control subjects and depressed patients: relationship to serotonin uptake and age.
Topics: Adult; Age Factors; Binding Sites; Blood Platelets; Depressive Disorder; Desipramine; Female; Fluoxetine; Humans; Imipramine; Infant; Male; Paroxetine; Serotonin | 1994 |
Occupancy of the serotonin transporter by fluoxetine, paroxetine, and sertraline: in vivo studies with [125I]RTI-55.
Topics: 1-Naphthylamine; Animals; Binding, Competitive; Brain Chemistry; Carrier Proteins; Cocaine; Fluoxetine; Hypothalamus; Iodine Radioisotopes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 1994 |
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline | 1994 |
The effect of 5-HT receptor ligands on the uptake of [3H]5-hydroxytryptamine into rat cortical synaptosomes.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cerebral Cortex; Cocaine; Desipramine; Female; Fluoxetine; In Vitro Techniques; Indoles; Neurotransmitter Uptake Inhibitors; Paroxetine; Piperazines; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Synaptosomes; Tropisetron | 1993 |
Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study.
Topics: Animals; Autoradiography; Brain Chemistry; Fluoxetine; Image Processing, Computer-Assisted; Ketanserin; Male; Mianserin; Paroxetine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Up-Regulation | 1993 |
Kinetics of the uptake of [3H]paroxetine in the rat brain.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipyrine; Autoradiography; Blood Volume; Blood-Brain Barrier; Brain; Fluoxetine; Male; Paroxetine; Rats; Rats, Wistar; Receptors, Serotonin; Tomography, Emission-Computed | 1993 |
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neuro
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Clorgyline; Desipramine; Fluoxetine; Hippocampus; Male; Mice; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Selegiline; Serotonin; Serotonin Receptor Agonists; Synaptic Transmission; Time Factors | 1993 |
Evidence that chronic administration of paroxetine or fluoxetine enhances 5-HT2 receptor function in the brain of the guinea pig.
Topics: Amitriptyline; Animals; Brain Chemistry; Calcimycin; Calcium; Cerebral Cortex; Female; Fluoxetine; Guinea Pigs; In Vitro Techniques; Inositol; Ketanserin; Male; Paroxetine; Phosphatidylinositols; Receptors, Serotonin; Serotonin; Serotonin Antagonists | 1993 |
Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain.
Topics: Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Brain; Dose-Response Relationship, Drug; Fluoxetine; Male; Paroxetine; Propylamines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Stereoisomerism | 1993 |
[3H]paroxetine binding and serotonin content of rat brain: absence of changes following antidepressant treatments.
Topics: Animals; Antidepressive Agents; Brain; Chromatography, High Pressure Liquid; Fluoxetine; Imipramine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Trimipramine | 1993 |
Recurrent hyponatremia associated with fluoxetine and paroxetine.
Topics: Aged; Depressive Disorder; Female; Fluoxetine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Recurrence | 1996 |
Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Libido; Middle Aged; Orgasm; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological | 1995 |
Pharmacokinetics of the newer antidepressants.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Desipramine; Fluoxetine; Humans; Isoenzymes; Liver; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder.
Topics: Animals; Dose-Response Relationship, Drug; Fluoxetine; Frontal Lobe; Guinea Pigs; Male; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Time Factors | 1995 |
Drug-drug interactions.
Topics: 1-Naphthylamine; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Depressive Disorder; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Mixed Function Oxygenases; Paroxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Affective Disorders, Psychotic; Aged; Ambulatory Care; Clozapine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Middle Aged; Paroxetine; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Sertraline; Stimulation, Chemical | 1996 |
The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva.
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Dothiepin; Female; Fluoxetine; Humans; Male; Middle Aged; Muscarinic Antagonists; Parotid Gland; Paroxetine; Potassium; Prospective Studies; Receptors, Muscarinic; Retrospective Studies; Saliva; Secretory Rate; Selective Serotonin Reuptake Inhibitors; Sodium; Xerostomia | 1995 |
Synthesis of 3 beta-aryl-8-azabicyclo[3.2.1]octanes with high binding affinities and selectivities for the serotonin transporter site.
Topics: Animals; Binding, Competitive; Carrier Proteins; Cocaine; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Frontal Lobe; Magnetic Resonance Spectroscopy; Membrane Glycoproteins; Membrane Transport Proteins; Molecular Structure; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship; Symporters; Tropanes | 1996 |
The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.
Topics: Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Fluoxetine; Humans; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1995 |
Synthesis and transporter binding properties of 3 beta-(4'-alkyl-, 4'-alkenyl-, and 4'-alkynylphenyl)nortropane-2 beta-carboxylic acid methyl esters: serotonin transporter selective analogs.
Topics: Animals; Binding, Competitive; Brain; Carrier Proteins; Cocaine; Dopamine; Dopamine Uptake Inhibitors; Fluoxetine; Membrane Glycoproteins; Membrane Transport Proteins; Molecular Structure; Nerve Tissue Proteins; Norepinephrine; Nortropanes; Paroxetine; Radioligand Assay; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Serotonin Receptor Agonists; Structure-Activity Relationship; Tropanes | 1996 |
3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine transporter.
Topics: Carrier Proteins; Cocaine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluoxetine; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Serotonin; Stereoisomerism; Structure-Activity Relationship | 1996 |
Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography.
Topics: 20-alpha-Dihydroprogesterone; Adrenalectomy; Animals; Brain; Castration; Fluoxetine; GABA Modulators; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Imipramine; Male; Paroxetine; Pregnanolone; Progesterone; Rats; Rats, Sprague-Dawley | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects.
Topics: 1-Naphthylamine; Aged; Anorexia; Antidepressive Agents; Depressive Disorder; Diarrhea; Fluoxetine; Fluvoxamine; Humans; Meta-Analysis as Topic; Nausea; Paroxetine; Patient Dropouts; Selective Serotonin Reuptake Inhibitors; Sertraline; Single-Blind Method | 1996 |
[Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Belgium; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Netherlands; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1996 |
Effects of antidepressants on the cytochrome P450 system.
Topics: 1-Naphthylamine; Antidepressive Agents; Cytochrome P-450 Enzyme System; Fluoxetine; Fluvoxamine; Humans; Medical Records; Paroxetine; Research Design; Sertraline | 1996 |
A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
Topics: 1-Naphthylamine; Adult; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Product Surveillance, Postmarketing; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome | 1996 |
[Adverse effects of selective serotonin uptake inhibitors. Hyponatremia caused by Schwartz-Bartter syndrome].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Antihypertensive Agents; Enalapril; Female; Fluoxetine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Fluoxetine-induced akathisia does not reappear after switch to paroxetine.
Topics: Akathisia, Drug-Induced; Depressive Disorder; Female; Fluoxetine; Hospitalization; Humans; Middle Aged; Paroxetine; Treatment Outcome | 1996 |
SSRI optimal dose remains at issue.
Topics: 1-Naphthylamine; Clinical Trials as Topic; Depressive Disorder; Drug Administration Schedule; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1997 |
Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Topics: 1-Naphthylamine; Aggression; Animals; Anxiety; Binding, Competitive; Citalopram; Depression; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Rats; Rats, Wistar; Receptors, sigma; Selective Serotonin Reuptake Inhibitors; Sertraline; Vocalization, Animal | 1997 |
Juvenile obsessive-compulsive disorder.
Topics: Adolescent; Child; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Female; Fluoxetine; Follow-Up Studies; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Personality Assessment; Prognosis; Treatment Outcome | 1997 |
Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat.
Topics: 1-Naphthylamine; Animals; Behavior, Animal; Chlorpromazine; Citalopram; Fluoxetine; Fluvoxamine; Guanidines; Haloperidol; Male; Microinjections; Motor Activity; Paroxetine; Piperidines; Posture; Rats; Rats, Sprague-Dawley; Receptors, sigma; Red Nucleus; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
Drug interaction potential of fluoxetine, sertraline, and paroxetine in four state psychiatric hospital populations.
Topics: 1-Naphthylamine; Antidepressive Agents; Drug Interactions; Fluoxetine; Humans; Paroxetine; Sertraline | 1997 |
Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
Topics: 1-Naphthylamine; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Bupropion; Dopamine Uptake Inhibitors; Female; Fluoxetine; Humans; Male; Middle Aged; Orgasm; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Surveys and Questionnaires | 1997 |
Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compound
Topics: Animals; Brain; Carrier Proteins; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Ligands; Magnetic Resonance Spectroscopy; Mass Spectrometry; Membrane Glycoproteins; Membrane Transport Proteins; Molecular Structure; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Nortropanes; Paroxetine; Piperazines; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Symporters | 1997 |
SSRI antidepressants and SIADH.
Topics: Aged; Female; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Vasopressins | 1997 |
Substitution of the selective serotonin reuptake inhibitors fluoxetine and paroxetine for the discriminative stimulus effects of ethanol in rats.
Topics: Animals; Central Nervous System Depressants; Conditioning, Operant; Discrimination, Psychological; Ethanol; Fluoxetine; Male; Paroxetine; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors | 1997 |
Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Desipramine; Fluoxetine; Fluvoxamine; Frozen Sections; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Lethal Dose 50; Microsomes, Liver; Mixed Function Oxygenases; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Venlafaxine Hydrochloride | 1997 |
Contributions of raphe-cortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex.
Topics: Afferent Pathways; Animals; Animals, Newborn; Axons; Brain Mapping; Cerebral Cortex; Female; Fluoxetine; Immunoenzyme Techniques; Male; Paroxetine; Raphe Nuclei; Rats; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Skin; Somatosensory Cortex; Thalamic Nuclei | 1997 |
Selective serotonin reuptake inhibitors plus pindolol. The REEP.
Topics: Depressive Disorder; Fluoxetine; Humans; Paroxetine; Pindolol; Selective Serotonin Reuptake Inhibitors; Sympatholytics | 1997 |
Interaction of serotonin re-uptake inhibitors with perhexiline.
Topics: Aged; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metabolic Clearance Rate; Paroxetine; Perhexiline; Selective Serotonin Reuptake Inhibitors; Vasodilator Agents | 1997 |
In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: sibutramine is a reuptake inhibitor.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Cyclobutanes; Fenfluramine; Fluoxetine; Male; Microdialysis; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin | 1997 |
Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen?
Topics: 1-Naphthylamine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Liver; Metabolic Clearance Rate; Mixed Function Oxygenases; Paroxetine; Psychotropic Drugs; Retrospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline | 1997 |
2'-Substitution of cocaine selectively enhances dopamine and norepinephrine transporter binding.
Topics: Animals; Binding, Competitive; Brain; Carrier Proteins; Cocaine; Dopamine; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Symporters | 1997 |
Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists | 1998 |
Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system.
Topics: 1-Naphthylamine; Adverse Drug Reaction Reporting Systems; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome; World Health Organization | 1997 |
Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Depressive Disorder; Direct Service Costs; Drug Costs; Fee-for-Service Plans; Female; Fluoxetine; Health Care Costs; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Male; Models, Econometric; Multivariate Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1998 |
Breast enlargement during chronic antidepressant therapy.
Topics: Breast; Breast Diseases; Cyclohexanols; Depressive Disorder; Female; Fluoxetine; Humans; Hyperplasia; Male; Menopause; Paroxetine; Prolactin; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride; Weight Gain | 1997 |
Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior | 1997 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bupropion; Drug Therapy, Combination; Female; Fluoxetine; Humans; Libido; Male; Middle Aged; Mood Disorders; Pain Measurement; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome | 1997 |
Hyponatraemia associated with the use of selective serotonin re-uptake inhibitors.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Dementia; Depressive Disorder; Drug Monitoring; Female; Fluoxetine; Humans; Hyponatremia; Male; Middle Aged; Paroxetine; Patient Admission; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sodium | 1998 |
The SSRI antidepressants: exploring their "other" possible properties.
Topics: 1-Naphthylamine; Adult; Aged; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Surveys and Questionnaires | 1998 |
Effects of prenatal cocaine exposure on serotonin and norepinephrine transporter density in the rat brain.
Topics: Aging; Animals; Brain; Carrier Proteins; Cocaine; Female; Fluoxetine; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Organ Specificity; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Reference Values; Serotonin; Serotonin Plasma Membrane Transport Proteins; Symporters | 1998 |
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding.
Topics: Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Carrier Proteins; Eating; Fluoxetine; Male; Mice; Mice, Inbred ICR; Motor Activity; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Paroxetine; Propylamines; Rats; Rats, Sprague-Dawley; Symporters | 1998 |
Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability.
Topics: Adult; Autistic Disorder; Drug Therapy, Combination; England; Female; Fluoxetine; Humans; Intellectual Disability; Male; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Social Behavior Disorders; Stereotyped Behavior; Treatment Outcome | 1998 |
Rapid response of emotional incontinence to selective serotonin reuptake inhibitors.
Topics: Adult; Affective Symptoms; Aged; Brain Injuries; Cerebrovascular Disorders; Crying; Fluoxetine; Humans; Laughter; Male; Middle Aged; Multiple Sclerosis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Discontinuation symptoms and SSRIs.
Topics: Biological Availability; Depressive Disorder; Dizziness; Fluoxetine; Follow-Up Studies; Half-Life; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 1998 |
Discontinuation of antidepressant therapy: emerging complications and their relevance.
Topics: Antidepressive Agents; Depressive Disorder; Fluoxetine; Humans; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Substance Withdrawal Syndrome; Syndrome; Terminology as Topic | 1998 |
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Topics: Adolescent; Adult; Child; Citalopram; Cytochrome P-450 Enzyme System; Drug Prescriptions; Fluoxetine; Fluvoxamine; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1998 |
Inhibition of hippocampal 5-HT synthesis by fluoxetine and paroxetine: evidence for the involvement of both 5-HT1A and 5-HT1B/D autoreceptors.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Enzyme Inhibitors; Fluoxetine; Hippocampus; Hydrazines; Male; Oxadiazoles; Paroxetine; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists | 1999 |
Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Excitatory Amino Acid Antagonists; Fluoxetine; Male; Motor Activity; Paroxetine; Phencyclidine; Rats; Rats, Sprague-Dawley | 1999 |
Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities.
Topics: Depressive Disorder; Drug Costs; Drug Prescriptions; Fluoxetine; Hospitals, Veterans; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 1999 |
Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
Topics: 1-Naphthylamine; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Drug Costs; Drug Utilization Review; Fluoxetine; Humans; Managed Care Programs; Models, Organizational; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; United States | 1995 |
Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people.
Topics: Aged; Antidepressive Agents, Second-Generation; Body Weight; Female; Fluoxetine; Humans; Hyponatremia; Male; Paroxetine; Retrospective Studies; Risk Factors; Time Factors | 1999 |
SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis.
Topics: Adult; Databases, Factual; Depressive Disorder; Drug Utilization; Episode of Care; Female; Fluoxetine; Humans; Logistic Models; Male; Multivariate Analysis; Paroxetine; Psychotherapy; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1999 |
Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Citalopram; Disease Models, Animal; Eating; Ethanol; Female; Fluoxetine; Fluvoxamine; Food Preferences; Male; Paroxetine; Rats; Rats, Mutant Strains; Selective Serotonin Reuptake Inhibitors | 1999 |
Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life.
Topics: Aging; Animals; Behavior, Animal; Brain Chemistry; Carrier Proteins; Fluoxetine; Growth; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Prefrontal Cortex; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins | 1999 |
Alteration of personality by serotonergic intervention.
Topics: Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Paroxetine; Personality; Personality Assessment; Placebos; Psychometrics; Research Design; Selective Serotonin Reuptake Inhibitors | 1999 |
Molecular cloning, expression and characterization of a bovine serotonin transporter.
Topics: Amino Acid Sequence; Animals; Carrier Proteins; Cattle; Citalopram; Cloning, Molecular; Desipramine; Female; Fluoxetine; HeLa Cells; Humans; Imipramine; Kinetics; Membrane Glycoproteins; Membrane Transport Proteins; Molecular Sequence Data; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Organ Specificity; Paroxetine; Phylogeny; Pregnancy; Rats; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Alignment; Sequence Homology, Amino Acid; Serotonin; Serotonin Plasma Membrane Transport Proteins; Transfection | 1999 |
[Proofs of efficacy].
Topics: Antidepressive Agents, Tricyclic; Clomipramine; Cyclohexanols; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Humans; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 1999 |
Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzamides; Benzodiazepines; Case-Control Studies; Contrast Media; Corpus Striatum; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Pyrrolidines; Receptors, Dopamine D2; Selective Serotonin Reuptake Inhibitors; Tomography, Emission-Computed, Single-Photon | 1999 |
New behavioral approach to trichotillomania.
Topics: Adolescent; Adult; Behavior Therapy; Child; Clomipramine; Combined Modality Therapy; Female; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Trichotillomania | 1999 |
Excretion of paroxetine into breast milk.
Topics: Adult; Breast Feeding; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine; Fluvoxamine; Humans; Lactation; Milk, Human; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Triglycerides | 1999 |
Modeling the pharmacoeconomic cost of three selective serotonin reuptake inhibitors.
Topics: Dose-Response Relationship, Drug; Fluoxetine; Follow-Up Studies; Humans; Mental Disorders; Mental Health Services; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 1999 |
Economic appraisal of citalopram in the management of single-episode depression.
Topics: Adult; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cohort Studies; Cost-Benefit Analysis; Depressive Disorder; Female; Fluoxetine; Health Maintenance Organizations; Humans; Male; Middle Aged; Paroxetine; Patient Care Team; Retrospective Studies; Sertraline | 1999 |
Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cost of Illness; Cost-Benefit Analysis; Depressive Disorder; Female; Fluoxetine; Follow-Up Studies; Health Care Costs; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 1999 |
Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes.
Topics: 3-alpha-Hydroxysteroid Dehydrogenase (B-Specific); 3-Hydroxysteroid Dehydrogenases; Amino Acid Sequence; Animals; Base Sequence; Brain; Cholestenone 5 alpha-Reductase; COS Cells; DNA, Complementary; Fluoxetine; Humans; Molecular Sequence Data; Oxidoreductases; Paroxetine; Pregnanolone; Progesterone; Rats; RNA, Messenger; Selective Serotonin Reuptake Inhibitors | 1999 |
The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat.
Topics: Animals; Conditioning, Operant; Differential Threshold; Fluoxetine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Reinforcement, Psychology; Selective Serotonin Reuptake Inhibitors; Sertraline | 1999 |
Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection.
Topics: Acetonitriles; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Humans; Hydrogen-Ion Concentration; Paroxetine; Quality Control; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 1999 |
Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Blood Platelets; Case-Control Studies; Clomipramine; Depressive Disorder; Female; Fluoxetine; Humans; Inositol 1,4,5-Trisphosphate; Male; Middle Aged; Paroxetine; Platelet Aggregation; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Time Factors | 1999 |
Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood.
Topics: Aging; Animals; Brain; Brain Stem; Carrier Proteins; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Female; Fluoxetine; Frontal Lobe; Ligands; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Nerve Tissue Proteins; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Piperazines; Presynaptic Terminals; Protein Binding; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Symporters; Tritium | 2000 |
Inhibitory effect of serotonergic drugs on contractile response of the rat vas deferens to electrical nerve stimulation: in vivo study.
Topics: Animals; Clomipramine; Electric Stimulation; Fluoxetine; Male; Muscle Contraction; Muscle, Smooth; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sertraline; Vas Deferens | 2000 |
Paroxetine binding to the rat norepinephrine transporter in vivo.
Topics: Animals; Biological Transport, Active; Calibration; Carrier Proteins; Chromatography, High Pressure Liquid; Fluoxetine; In Vitro Techniques; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Spectrophotometry, Ultraviolet; Symporters | 2000 |
Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications.
Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Infant, Newborn; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2000 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Fluorometry; Fluoxetine; Fluvoxamine; Humans; Linear Models; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline | 2000 |
Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Autoreceptors; Fluoxetine; Gene Expression; In Situ Hybridization; Male; Nortriptyline; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; RNA, Messenger; Sertraline | 2000 |
Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine.
Topics: Animals; Appetite Depressants; Brain; Cyclobutanes; Dexfenfluramine; Fluoxetine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists | 2000 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Do antidepressants affect motivation in conditioned place preference?
Topics: Adrenergic Uptake Inhibitors; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Cocaine; Conditioning, Psychological; Cyclobutanes; Cyclohexanols; Dose-Response Relationship, Drug; Fluoxetine; Male; Motivation; Norepinephrine; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2000 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Meta-Analysis as Topic; Paroxetine; Personality Inventory; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome | 2001 |
Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs.
Topics: Animals; Benzhydryl Compounds; Fenfluramine; Fluoxetine; Frontal Lobe; In Vitro Techniques; Male; Modafinil; Neuroprotective Agents; Paroxetine; Potassium; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Sleep; Synaptic Transmission; Synaptosomes; Tritium | 2001 |
Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors.
Topics: Aged; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Child, Preschool; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluoxetine; Humans; Hydroxylation; Male; Microsomes, Liver; Middle Aged; Paroxetine; Phenytoin; Selective Serotonin Reuptake Inhibitors; Sertraline; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Using forecasting models to estimate the effects of changes in the composition of claims for selective serotonin reuptake inhibitors on expenditures.
Topics: Adult; Antidepressive Agents; Cross-Sectional Studies; Drug Costs; Fluoxetine; Fluvoxamine; Forecasting; Humans; Insurance Claim Reporting; Insurance, Pharmaceutical Services; Middle Aged; Models, Theoretical; Ontario; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Prefrontal changes and treatment response prediction in depression.
Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Sertraline; Venlafaxine Hydrochloride | 2001 |
Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters.
Topics: Animals; Brain Chemistry; Carrier Proteins; Central Nervous System Stimulants; Dopamine Plasma Membrane Transport Proteins; Fluoxetine; Kinetics; Ligands; Membrane Glycoproteins; Membrane Transport Proteins; Membranes; Mesencephalon; Methylphenidate; Neostriatum; Nerve Tissue Proteins; Paroxetine; Piperazines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2001 |
Economic evaluation of major selective serotonin-reuptake inhibitors in a managed care population.
Topics: Adolescent; Adult; Depressive Disorder; Drug Costs; Episode of Care; Fluoxetine; Humans; Managed Care Programs; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2001 |
Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Benzimidazoles; Drug Interactions; Fluoxetine; Imipramine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Serotonin Syndrome | 2001 |
Comparison of peripheral inhibitory effects of clomipramine with selective serotonin re-uptake inhibitors on contraction of vas deferens: in vitro and in vivo studies.
Topics: Adult; Antidepressive Agents, Tricyclic; Clomipramine; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Humans; Male; Muscle Contraction; Muscle, Smooth; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Vas Deferens | 2001 |
Does mirtazapine have a more rapid onset than SSRIs?
Topics: Antidepressive Agents, Tricyclic; Citalopram; Cross-Sectional Studies; Data Interpretation, Statistical; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Mianserin; Mirtazapine; Paroxetine; Patient Dropouts; Placebo Effect; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2001 |
Male breast neoplasia in association with selective serotonin re-uptake inhibitor therapy: a report of three cases.
Topics: Aged; Antidepressive Agents, Second-Generation; Breast Neoplasms, Male; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors | 2001 |
Mood disorders in children and adolescents: psychopharmacological treatment.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Health Services Needs and Demand; Humans; Imipramine; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
Amotivational syndrome associated with selective serotonin reuptake inhibitors in children and adolescents.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Female; Fluoxetine; Humans; Male; Motivation; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2001 |
[The transfer of selective serotonin reuptake inhibitors to human milk].
Topics: Antidepressive Agents; Breast Feeding; Citalopram; Depression, Postpartum; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Milk, Human; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
Remission of SSRI-induced akathisia after switch to nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 2001 |
Serotonin reuptake inhibitor antidepressants and pregnancy: many unanswered questions.
Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Child; Child, Preschool; Clinical Trials as Topic; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Infant; Infant, Newborn; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 1999 |
The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Topics: Animals; Binding, Competitive; Body Temperature; Brain; Cerebral Cortex; Fluoxetine; Fluvoxamine; Indoles; Male; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Neuroprotective Agents; Paroxetine; Rats; Rectum; Serotonin; Serotonin Agents; Time Factors; Tritium | 2001 |
Balance control and posture in anxious mice improved by SSRI treatment.
Topics: Animals; Anxiety; Central Nervous System; Dose-Response Relationship, Drug; Female; Fluoxetine; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Paroxetine; Postural Balance; Posture; Selective Serotonin Reuptake Inhibitors; Sex Characteristics; Vestibular Diseases | 2001 |
Post-stroke depression, antidepressant treatment and rehabilitation results. A case-control study.
Topics: Activities of Daily Living; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Case-Control Studies; Depression; Disabled Persons; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Activity; Paroxetine; Recovery of Function; Stroke; Stroke Rehabilitation | 2001 |
The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization.
Topics: Adolescent; Adult; Cohort Studies; Cost Savings; Drug Costs; Emergency Service, Hospital; Female; Fluoxetine; Health Care Costs; Humans; Insurance Claim Review; Laboratories; Laboratories, Hospital; Male; Managed Care Programs; Middle Aged; Panic Disorder; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2001 |
LY393558, a 5-hydroxytryptamine reuptake inhibitor and 5-HT(1B/1D) receptor antagonist: effects on extracellular levels of 5-hydroxytryptamine in the guinea pig and rat.
Topics: Administration, Oral; Animals; Cyclic S-Oxides; Dose-Response Relationship, Drug; Extracellular Space; Female; Fenfluramine; Fluoxetine; Frontal Lobe; Guinea Pigs; Hypothalamus; Injections, Intraperitoneal; Male; Oxadiazoles; Paroxetine; Piperazines; Rats; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Tetrodotoxin; Thiadiazines; Time Factors | 2001 |
Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma by temperature-programmed packed capillary liquid chromatography with on-column focusing of large injection volumes.
Topics: Chromatography, Liquid; Citalopram; Fluoxetine; Humans; Paroxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2002 |
Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Topics: Adolescent; Adult; Depressive Disorder; Drug Administration Schedule; Drug Costs; Female; Fluoxetine; Health Care Costs; Health Maintenance Organizations; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Time Factors | 2002 |
5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors.
Topics: Apoptosis; Biopsy; Blotting, Western; Burkitt Lymphoma; Carrier Proteins; Caspases; Cell Survival; Citalopram; DNA Damage; DNA, Neoplasm; Fluoxetine; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tumor Cells, Cultured | 2002 |
Is one selective serotonin reuptake inhibitor better than another?
Topics: Antidepressive Agents; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Is one selective serotonin reuptake inhibitor better than another?
Topics: Antidepressive Agents; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Is one selective serotonin reuptake inhibitor better than another?
Topics: Antidepressive Agents; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Is one selective serotonin reuptake inhibitor better than another?
Topics: Antidepressive Agents; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Are paroxetine, fluoxetine, and sertraline equally effective for depression?
Topics: Adult; Depressive Disorder; Evidence-Based Medicine; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.
Topics: Animals; Antipsychotic Agents; Binding Sites; Biological Transport; Brain; Brain Chemistry; Clozapine; Drug Administration Schedule; Fluoxetine; Haloperidol; In Situ Hybridization; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neuropeptides; Paroxetine; Piperazines; Rats; Tetrabenazine; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2002 |
SSRIs: take your pick.
Topics: Depression; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Variations in antidepressant prescribing practice: clinical need or market influences?
Topics: Antidepressive Agents; Community Psychiatry; Drug Utilization Review; Fluoxetine; Humans; Marketing; Paroxetine; Physicians, Family; Practice Patterns, Physicians'; Sertraline; Surveys and Questionnaires | 2002 |
Effect of isolation rearing on pre- and post-synaptic serotonergic function in the rat dorsal hippocampus.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Carbachol; Cholinergic Agonists; Fluoxetine; Hippocampus; In Vitro Techniques; Male; Motor Activity; Neurons; Paroxetine; Presynaptic Terminals; Rats; Rats, Inbred Strains; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Social Isolation; Synapses | 2003 |
A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder.
Topics: Adult; California; Depressive Disorder, Major; Drug Costs; Drug Utilization Review; Female; Fluoxetine; Humans; Insurance Claim Review; Male; Medicaid; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors | 2002 |
Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Fluoxetine; Male; Microdialysis; Norepinephrine; Paroxetine; Piperazines; Prefrontal Cortex; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Venlafaxine Hydrochloride | 2002 |
Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells.
Topics: Apoptosis; B-Lymphocytes; Burkitt Lymphoma; Calcium Signaling; Carrier Proteins; Citalopram; Fluoxetine; Gene Expression Regulation; Genes, bcl-2; Genes, myc; Humans; Membrane Glycoproteins; Membrane Transport Proteins; Monocytes; Monomeric GTP-Binding Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Nerve Tissue Proteins; NM23 Nucleoside Diphosphate Kinases; Nucleoside-Diphosphate Kinase; Paroxetine; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Transcription Factors | 2003 |
Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Topics: Citalopram; Clinical Pharmacy Information Systems; Cost Control; Cost Savings; Drug Administration Schedule; Drug Costs; Drug Utilization; Fluoxetine; Fluvoxamine; Hospital Costs; Hospitals, Veterans; Humans; Mental Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2003 |
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Humans; Microsomes, Liver; Paroxetine; Quinidine | 2003 |
Serotonin transporter modulation in blood lymphocytes from patients with major depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Proteins; Depressive Disorder, Major; Down-Regulation; Female; Fluoxetine; Humans; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Neuroimmunomodulation; Paroxetine; Radioligand Assay; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Up-Regulation | 2002 |
Drug-related hyperprolactinemia.
Topics: Antidepressive Agents; Antipsychotic Agents; Female; Flunarizine; Fluoxetine; Fluvoxamine; Humans; Hyperprolactinemia; Indoramin; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sulpiride | 2003 |
Clinical practice guidelines for depression in young people.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Child; Depressive Disorder; Fluoxetine; Humans; Meta-Analysis as Topic; Paroxetine; Placebos; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Assessment; Selective Serotonin Reuptake Inhibitors | 2003 |
Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Utilization Review; Fluoxetine; Health Maintenance Organizations; Hospitalization; Humans; Medical Audit; Midwestern United States; Paroxetine; Retrospective Studies; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline | 2002 |
Placental passage of antidepressant medications.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fetal Blood; Fluoxetine; Humans; Maternal-Fetal Exchange; Paroxetine; Placenta; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Sertraline | 2003 |
[Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants].
Topics: Adult; Antidepressive Agents; Doxepin; Female; Fluoxetine; Follow-Up Studies; Humans; Irritable Bowel Syndrome; Male; Middle Aged; Paroxetine; Quality of Life | 2003 |
Methylenendioxyamphetamine produces serotonin nerve terminal loss and diminished behavioural and neurochemical responses to the antidepressant fluoxetine.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Antidepressive Agents; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Fluoxetine; Hallucinogens; Hydroxyindoleacetic Acid; Male; Paroxetine; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Serotonin | 2003 |
Psychopharmacological treatment of major depressive disorder in children and adolescents.
Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide | 2003 |
Selective serotonin reuptake inhibitors in pilot fatalities of civil aviation accidents, 1990-2001.
Topics: Accidents, Aviation; Aerospace Medicine; Certification; Citalopram; Databases as Topic; Environmental Monitoring; Fluoxetine; Humans; Paroxetine; Postmortem Changes; Selective Serotonin Reuptake Inhibitors; Sertraline; Survival Rate; United States | 2003 |
Which SSRI?
Topics: Adolescent; Anxiety; Child; Depressive Disorder; Drug Interactions; Fluoxetine; Half-Life; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Selective Serotonin Reuptake Inhibitors; Suicide Prevention | 2003 |
Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.
Topics: Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Genotype; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors | 2003 |
Different effects of selective serotonin reuptake inhibitors on a patient suffering from panic disorder.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Fluvoxamine; Humans; Hypnotics and Sedatives; Male; Panic Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Regulation of the norepinephrine transporter by chronic administration of antidepressants.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Autoradiography; Brain; Cerebral Cortex; Desipramine; Fluoxetine; Hippocampus; In Situ Hybridization; Locus Coeruleus; Male; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Symporters | 2004 |
In vivo rat model to measure hypogastric nerve stimulation-induced seminal vesicle and vasal pressure responses simultaneously.
Topics: Animals; Clomipramine; Electric Stimulation; Fluoxetine; Hypogastric Plexus; In Vitro Techniques; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Seminal Vesicles; Serotonin; Sertraline; Vas Deferens | 2004 |
Antidepressant medications in children.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Causality; Child; Depressive Disorder; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Suicide | 2004 |
Are selective serotonin re-uptake inhibitors associated with an increased risk of self-harm by antidepressant overdose?
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Doxepin; Drug Overdose; Drug Prescriptions; Emergency Service, Hospital; Female; Fluoxetine; Humans; Imipramine; Information Services; Male; Mianserin; Mirtazapine; Paroxetine; Patient Admission; Patient Readmission; Poison Control Centers; Retrospective Studies; Risk Assessment; Scotland; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sertraline; Trazodone; Venlafaxine Hydrochloride | 2004 |
Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Topics: Adult; Benzylamines; Carbon Radioisotopes; Carrier Proteins; Citalopram; Corpus Striatum; Cyclohexanols; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline; Tomography, Emission-Computed; Venlafaxine Hydrochloride | 2004 |
Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Desipramine; Dopamine beta-Hydroxylase; Droxidopa; Fluoxetine; Gene Deletion; Mice; Morpholines; Norepinephrine; Paroxetine; Reboxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Tail | 2004 |
Changes in energy after switching from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine.
Topics: Citalopram; Depressive Disorder; Drug Administration Schedule; Fatigue; Fluoxetine; Humans; Paroxetine; Quality of Life; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Neonatal complications after intrauterine exposure to SSRI antidepressants.
Topics: Antidepressive Agents; Citalopram; Depression; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; France; Humans; Infant, Newborn; Neonatal Abstinence Syndrome; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline | 2004 |
Lilly goes off Prozac.
Topics: Administrative Personnel; Adolescent; Antidepressive Agents, Second-Generation; Child; Drug Industry; Drugs, Generic; Economic Competition; Fluoxetine; Humans; Investments; Leadership; Marketing; Paroxetine; Patents as Topic; Planning Techniques; Research Support as Topic; United States | 2004 |
Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats.
Topics: Acute Disease; Amines; Amitriptyline; Animals; Conscious Sedation; Cyclohexanecarboxylic Acids; Cyclohexanols; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Duloxetine Hydrochloride; Fluoxetine; Formaldehyde; Gabapentin; gamma-Aminobutyric Acid; Male; Methyltyrosines; Milnacipran; Neuromuscular Junction; Norepinephrine; p-Chloroamphetamine; Pain; Paroxetine; Rats; Rats, Sprague-Dawley; Serotonin; Thiophenes; Venlafaxine Hydrochloride | 2004 |
Antidepressants and the risk of suicidal behaviors.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Amitriptyline; Antidepressive Agents; Case-Control Studies; Child; Dothiepin; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted; United Kingdom | 2004 |
Psychopharmacology in the New York Times.
Topics: Adolescent; Child; Depressive Disorder; Fluoxetine; Humans; Newspapers as Topic; Paroxetine; Psychopharmacology; Selective Serotonin Reuptake Inhibitors | 2004 |
[Unfortunate title?].
Topics: Adolescent; Child; Depression; Fluoxetine; Humans; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors | 2004 |
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2004 |
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Topics: Animals; Antidepressive Agents; Clorgyline; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Hindlimb Suspension; Male; Mice; Morpholines; Motor Activity; Paroxetine; Pyrazoles; Pyrimidines; Pyrroles; Reboxetine; Receptors, Corticotropin-Releasing Hormone; Selegiline; Swimming; Tranylcypromine; Triazines | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; Drug Therapy; Fluoxetine; Humans; Paroxetine; Patient Satisfaction; Primary Health Care; Psychiatry; Psychology; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Sertraline; Social Work | 2004 |
Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia.
Topics: Animals; Citalopram; Cladocera; Ecosystem; Female; Fluoxetine; Fluvoxamine; Lethal Dose 50; Male; No-Observed-Adverse-Effect Level; Paroxetine; Reproduction; Selective Serotonin Reuptake Inhibitors; Sertraline; Toxicity Tests, Acute; Toxicity Tests, Chronic; Water Pollutants, Chemical | 2004 |
In vivo identification and characterization of binding sites for selective serotonin reuptake inhibitors in mouse brain.
Topics: Analysis of Variance; Animals; Area Under Curve; Binding Sites; Brain; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Male; Mice; Mice, Inbred ICR; Paroxetine; Radioligand Assay; Receptors, Serotonin; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Tritium | 2004 |
Fluvoxamine: new indication. No progress in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Child; Drug Approval; Fluoxetine; France; Humans; Obsessive-Compulsive Disorder; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2004 |
Antidepressants and the risk of suicidal behaviors.
Topics: Amitriptyline; Antidepressive Agents; Dothiepin; Fluoxetine; Humans; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors; Suicide | 2004 |
Selective serotonin reuptake inhibitors induce spontaneous interneuronal activity in the leech nervous system.
Topics: Action Potentials; Adrenergic Uptake Inhibitors; Animals; Citalopram; Drug Interactions; Electric Stimulation; Fluoxetine; Ganglia, Invertebrate; Imipramine; In Vitro Techniques; Interneurons; Leeches; Membrane Potentials; Neural Networks, Computer; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Synapses | 2005 |
DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Area Under Curve; Blood Pressure; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Evaluation, Preclinical; Electric Stimulation; Erectile Dysfunction; Fluoxetine; Injections, Intravenous; Male; Nitric Oxide; Nitric Oxide Synthase; Paroxetine; Penile Erection; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pressure; Pyrimidines; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sulfonamides | 2005 |
Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors.
Topics: Animals; Behavior, Animal; Binding Sites; Brain; Fluoxetine; Fluvoxamine; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred ICR; Motor Activity; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2005 |
Simultaneous determination of fluoxetine, citalopram, paroxetine, venlafaxine in plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI).
Topics: Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Citalopram; Cyclohexanols; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Venlafaxine Hydrochloride | 2005 |
Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation.
Topics: Adult; Citalopram; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Netherlands; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Surveys and Questionnaires; Time Factors | 2005 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal Relations; Male; Panic Disorder; Paroxetine; Pilot Projects; Problem Solving; Psychotherapy; Quality of Life; Selective Serotonin Reuptake Inhibitors | 2005 |
Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Desipramine; Electroshock; Fluoxetine; Male; Membrane Transport Proteins; Paroxetine; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tissue Distribution; Vesicular Glutamate Transport Protein 1; Vesicular Glutamate Transport Protein 2; Vesicular Glutamate Transport Proteins | 2005 |
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Topics: Adult; Adverse Drug Reaction Reporting Systems; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Patient Dropouts; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Factors; Time Factors; Treatment Outcome | 2005 |
Antidepressants and suicide: a commentary on a significant contribution to this debate.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Child; Depression; Dothiepin; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted; Time Factors; United Kingdom | 2005 |
Dysphonia induced by selective serotonin reuptake inhibitors.
Topics: Aged; Female; Fluoxetine; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Voice Disorders | 2005 |
Influence of fluoxetine and paroxetine in behavioral sensitization induced by ethanol in mice.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Central Nervous System Depressants; Ethanol; Exploratory Behavior; Fear; Fluoxetine; Male; Mice; Motor Activity; Paroxetine | 2005 |
Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice.
Topics: Animals; Anti-Dyskinesia Agents; Catalepsy; Disease Models, Animal; Female; Fluoxetine; Haloperidol; Male; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Time Factors | 2005 |
Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Topics: Action Potentials; Allosteric Regulation; Animals; Antidepressive Agents, Second-Generation; Brain; Chlorocebus aethiops; Citalopram; COS Cells; Drug Interactions; Fluoxetine; Hippocampus; Male; Microdialysis; Paroxetine; Protein Binding; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Transfection | 2007 |
Selective serotonin reuptake inhibitors in sewage influents and effluents from Tromsø, Norway.
Topics: Calibration; Chemical Fractionation; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Fluvoxamine; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline; Sewage; Water Pollutants, Chemical | 2006 |
I have read about a new study that showed antidepressants can increase the risk of abdominal bleeding. I'm currently taking Prozac, and my husband takes Zoloft. Should we worry?
Topics: Antidepressive Agents; Drug Interactions; Female; Fluoxetine; Gastrointestinal Hemorrhage; Humans; Male; Paroxetine; Polypharmacy; Sertraline | 2006 |
Antidepressant therapy and C-reactive protein levels.
Topics: Adult; Aged; C-Reactive Protein; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2006 |
Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety.
Topics: Adrenergic alpha-Antagonists; Alprazolam; Animals; Anxiety; Citalopram; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Hypnotics and Sedatives; Male; Motor Activity; Panic Disorder; Paroxetine; Periaqueductal Gray; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Stereotaxic Techniques; Yohimbine | 2006 |
Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine.
Topics: Animals; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Fluoxetine; Head Movements; Locomotion; Methamphetamine; Mice; Paroxetine; Psychoses, Substance-Induced; Secondary Prevention; Selective Serotonin Reuptake Inhibitors | 2007 |
Prevalence and patterns of antidepressant drug use during pregnancy.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Benzodiazepines; Databases, Factual; Depressive Disorder; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization Review; Female; Fluoxetine; Humans; Insurance, Pharmaceutical Services; Netherlands; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimesters; Prevalence; Time Factors | 2006 |
Night sweats and elevated follicle-stimulating hormone levels while taking selective serotonin reuptake inhibitors.
Topics: Adult; Depression; Female; Fluoxetine; Follicle Stimulating Hormone; Humans; Infertility, Female; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sweating | 2006 |
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Chemistry; Carrageenan; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Duloxetine Hydrochloride; Edema; Fluoxetine; Hot Temperature; Hyperalgesia; Male; Norepinephrine; Paroxetine; Pressure; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Thiophenes; Venlafaxine Hydrochloride | 2006 |
Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Topics: Adolescent; Adult; Aged; Catchment Area, Health; Citalopram; Cost-Benefit Analysis; Depressive Disorder; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluoxetine; Health Expenditures; Humans; Male; Middle Aged; Paroxetine; Primary Health Care; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Spain | 2006 |
Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze.
Topics: Analysis of Variance; Animals; Behavior, Animal; Desipramine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Male; Maze Learning; Paroxetine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors | 2007 |
Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study.
Topics: Action Potentials; Analysis of Variance; Animals; Citalopram; Dopamine; Drug Administration Schedule; Fluoxetine; Male; Mesencephalon; Neurons; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2007 |
Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6 Inhibitors; Drug Monitoring; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Quinolones | 2006 |
Selective serotonin reuptake inhibitors reduce the attack frequency in familial mediterranean Fever.
Topics: Acute-Phase Reaction; Adolescent; Adult; Blood Sedimentation; C-Reactive Protein; Colchicine; Depression; Drug Therapy, Combination; Familial Mediterranean Fever; Female; Fibrinogen; Fibromyalgia; Fluoxetine; Humans; Leukocyte Count; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
Topics: Cross-Sectional Studies; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Medication Errors; Middle Aged; Paroxetine; Retrospective Studies; Risk; Selective Serotonin Reuptake Inhibitors; Sertraline; Veterans | 2007 |
L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression.
Topics: Adult; Bipolar Disorder; Clomipramine; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine; Treatment Outcome | 2007 |
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2007 |
Simple options for improving signal detection in antidepressant clinical trials.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Fluoxetine; Likelihood Functions; Models, Statistical; Paroxetine; Personality Inventory; Placebo Effect; Psychometrics; Reproducibility of Results; Research Design; Signal Detection, Psychological; Thiophenes; Treatment Outcome | 2007 |
Associations between the use of common medications and sleep architecture in patients with untreated obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Antidepressive Agents; Aspirin; Drug Therapy; Female; Fluoxetine; Health Status; Humans; Male; Middle Aged; Paroxetine; Polysomnography; Retrospective Studies; Sleep Apnea, Obstructive; Sleep, REM; Treatment Refusal | 2006 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Utilization Review; Female; Fluoxetine; Humans; Hyperprolactinemia; Italy; Male; Medical Records; Mental Disorders; Olanzapine; Paroxetine; Practice Patterns, Physicians'; Retrospective Studies; Risperidone; Sertraline; Treatment Outcome | 2008 |
Analysis of paroxetine, fluoxetine and norfluoxetine in fish tissues using pressurized liquid extraction, mixed mode solid phase extraction cleanup and liquid chromatography-tandem mass spectrometry.
Topics: Animals; Chromatography, Liquid; Fishes; Fluoxetine; Molecular Structure; Paroxetine; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2007 |
The guinea pig forced swim test as a new behavioral despair model to characterize potential antidepressants.
Topics: Amitriptyline; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Clozapine; Desipramine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drugs, Investigational; Fluoxetine; Guinea Pigs; Injections, Intraperitoneal; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Selective Serotonin Reuptake Inhibitors; Swimming; Tranylcypromine | 2007 |
Benefits and harms of pediatric antidepressant medications.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors | 2007 |
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
Topics: Aged; Aged, 80 and over; Algorithms; Bayes Theorem; Citalopram; Cost-Benefit Analysis; Depression; Drugs, Generic; Female; Fluoxetine; Humans; Male; Medicare; Models, Statistical; Paroxetine; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States | 2007 |
Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
Topics: Adult; Citalopram; Clomipramine; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Demography; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2007 |
Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Behavior, Animal; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Exploratory Behavior; Fluoxetine; Hindlimb Suspension; Male; Maze Learning; Mice; Motor Activity; Olfactory Bulb; Ondansetron; Paroxetine; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Agonists; Serotonin 5-HT3 Receptor Antagonists; Stress, Psychological; Venlafaxine Hydrochloride | 2008 |
Clinical inquiries. What's the best drug treatment for premature ejaculation?
Topics: Anesthetics, Local; Antidepressive Agents; Clomipramine; Ejaculation; Fluoxetine; Humans; Lidocaine; Lidocaine, Prilocaine Drug Combination; Male; Paroxetine; Phosphodiesterase Inhibitors; Prilocaine; Sertraline; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Treatment Outcome | 2008 |
Cerebral metabolic effects of fluoxetine, fluvoxamine, paroxetine and sertraline in the conscious rat.
Topics: Animals; Brain; Brain Mapping; Carbon Isotopes; Deoxyglucose; Dose-Response Relationship, Drug; Fluoxetine; Male; Paroxetine; Radionuclide Imaging; Rats; Rats, Inbred F344; Selective Serotonin Reuptake Inhibitors; Sertraline; Wakefulness | 2008 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression.
Topics: Amino Acids; Amphetamine; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Darkness; Depression; Diazepam; Fever; Fluoxetine; Light; Male; Mice; Paroxetine; Receptors, Metabotropic Glutamate; Reinforcement Schedule; Stress, Psychological; Xanthenes | 2008 |
Flat dose-response curves for efficacy: what do they mean to the clinician?
Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Physicians; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; United States; United States Food and Drug Administration | 2008 |
Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.
Topics: Abnormalities, Drug-Induced; Abortion, Induced; Adult; Antidepressive Agents, Second-Generation; Birth Weight; Case-Control Studies; Confidence Intervals; Drug Administration Schedule; Female; Fluoxetine; Gestational Age; Heart Defects, Congenital; Humans; Infant, Newborn; Maternal Age; Odds Ratio; Paroxetine; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Risk; Selective Serotonin Reuptake Inhibitors | 2008 |
Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Topics: Animals; Behavior, Animal; Brain Chemistry; Cerebral Cortex; Drug Interactions; Fluoxetine; Hallucinogens; Immobility Response, Tonic; Male; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin; Swimming; Time Factors; Tritium | 2008 |
Selective serotonin reuptake inhibitors modify physiological gastrointestinal motor activities via 5-HT2c receptor and acyl ghrelin.
Topics: Animals; Drugs, Chinese Herbal; Eating; Fenfluramine; Fluoxetine; Fluvoxamine; Gastrointestinal Motility; Ghrelin; Growth Hormone; Injections, Intraventricular; Male; Oligopeptides; Paroxetine; Piperazines; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT2C; Receptors, Ghrelin; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists | 2009 |
Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.
Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Case-Control Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Nortriptyline; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sex Factors | 2009 |
Lipidomic analyses of the mouse brain after antidepressant treatment: evidence for endogenous release of long-chain fatty acids?
Topics: Animals; Antidepressive Agents; Basal Ganglia; Brain; Ceramides; Cerebellum; Chromatography, High Pressure Liquid; Fatty Acids; Fluoxetine; Hippocampus; Injections, Intraperitoneal; Lysophospholipids; Male; Maprotiline; Mice; Mice, Inbred BALB C; Paroxetine; Phosphatidylcholines; Phospholipases A2; Prefrontal Cortex; Spectrometry, Mass, Electrospray Ionization; Sphingomyelins; Time Factors | 2009 |
Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.
Topics: Adult; Birth Weight; Case-Control Studies; Citalopram; Female; Fetal Blood; Fetal Development; Fetal Growth Retardation; Fetus; Fluoxetine; Hormones; Humans; Hypothalamo-Hypophyseal System; Infant, Newborn; Insulin-Like Growth Factor I; Male; Paroxetine; Pituitary-Adrenal System; Placenta; Pregnancy; Selective Serotonin Reuptake Inhibitors | 2009 |
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases as Topic; Depression; Drug Costs; Drug Prescriptions; Drugs, Generic; Female; Fluoxetine; Humans; Insurance, Pharmaceutical Services; Likelihood Functions; Logistic Models; Male; Medication Adherence; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors; United States | 2009 |
Inhibitory effect of selective serotonin reuptake inhibitors on the vesicular monoamine transporter 2.
Topics: Animals; Dopamine; Fluoxetine; Fluvoxamine; Haloperidol; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Rats; Rats, Wistar; Reserpine; Selective Serotonin Reuptake Inhibitors; Synaptic Vesicles; Vesicular Monoamine Transport Proteins | 2009 |
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line.
Topics: Adenosine Deaminase; Amitriptyline; Amyotrophic Lateral Sclerosis; Antidepressive Agents; Arginine; Cyclopropanes; Desipramine; Fluoxetine; Fluvoxamine; Glutamine; HeLa Cells; Humans; Imipramine; Milnacipran; Morpholines; Paroxetine; Reboxetine; Receptors, AMPA; RNA Editing; RNA-Binding Proteins; RNA, Messenger | 2009 |
Fast separation of selective serotonin reuptake inhibitors antidepressants in plasma sample by nonaqueous capillary electrophoresis.
Topics: Antidepressive Agents; Citalopram; Drug Monitoring; Electrophoresis, Capillary; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2009 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Movement Disorders; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2010 |
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.
Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tryptophan Hydroxylase; Young Adult | 2009 |
Solid-phase extraction and analysis of paroxetine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry.
Topics: Calibration; Chromatography, High Pressure Liquid; Fluoxetine; Humans; Indicators and Reagents; Paroxetine; Plasma; Reference Standards; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Spectrometry, Mass, Electrospray Ionization | 2010 |
Depletion of selective serotonin reuptake inhibitors during sewage sludge composting.
Topics: Bacteria, Aerobic; Biodegradation, Environmental; Bioreactors; Chromatography, High Pressure Liquid; Citalopram; Fluoxetine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sewage; Soil Pollutants; Waste Disposal, Fluid | 2009 |
Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur.
Topics: Case-Control Studies; Echocardiography; Female; Fluoxetine; Heart Murmurs; Humans; Infant, Newborn; Maternal Exposure; Paroxetine; Pregnancy; Prevalence; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Teratogens | 2009 |
Paroxetine inhibited the relaxations induced by EFS in mice corpus cavernosum: is it a NOS inhibition?
Topics: Animals; Dose-Response Relationship, Drug; Electric Stimulation; Fluoxetine; Male; Mice; Mice, Inbred BALB C; Muscle Relaxation; Muscle, Smooth; Nitric Oxide; Nitric Oxide Synthase; Paroxetine; Penis; Phenylephrine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2010 |
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Fluoxetine; Humans; Male; Multicenter Studies as Topic; Paroxetine; Personality Assessment; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Venlafaxine Hydrochloride | 2009 |
Acute and chronic treatment with serotonin reuptake inhibitors exert opposite effects on respiration in rats: possible implications for panic disorder.
Topics: Animals; Drug Administration Schedule; Fluoxetine; Male; Panic Disorder; Paroxetine; Piperazines; Pyridines; Rats; Rats, Wistar; Respiration; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Synapses | 2010 |
Agomelatine: new drug. Adverse effects and no proven efficacy.
Topics: Acetamides; Animals; Antidepressive Agents; Bias; Carcinogens; Clinical Trials as Topic; Cyclohexanols; Depression; Depressive Disorder; Double-Blind Method; Drug Approval; Europe; Fluoxetine; Humans; Hypnotics and Sedatives; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptors, Melatonin; Recurrence; Selective Serotonin Reuptake Inhibitors; Suicide; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Inhibitory mechanisms and binding site location for serotonin selective reuptake inhibitors on nicotinic acetylcholine receptors.
Topics: Animals; Binding Sites; Binding, Competitive; Calcium Signaling; Cell Line; Cell Membrane; Dizocilpine Maleate; Electric Organ; Fluoxetine; Humans; Ligands; Models, Molecular; Molecular Conformation; Muscles; Nicotinic Agonists; Nicotinic Antagonists; Paroxetine; Protein Isoforms; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors; Torpedo | 2010 |
Deaths involving serotonergic drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Australia; Cause of Death; Citalopram; Cyclohexanols; Female; Fluoxetine; Forensic Toxicology; Gas Chromatography-Mass Spectrometry; Humans; Male; Middle Aged; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine; Serotonin Agents; Sertraline; Tramadol; Venlafaxine Hydrochloride | 2010 |
Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.
Topics: Androstenes; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Fluoxetine; Humans; Mineralocorticoid Receptor Antagonists; Models, Economic; Paroxetine; Premenstrual Syndrome; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2010 |
SSRIs and tamoxifen. Why condemn fluoxetine?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen | 2010 |
Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts.
Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Cohort Studies; Cross-Sectional Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide; Suicide Prevention; Suicide, Attempted | 2010 |
Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Topics: Adult; Aged; Antidepressive Agents; British Columbia; Cause of Death; Citalopram; Cohort Studies; Depressive Disorder; Female; Fluoxetine; Fluvoxamine; Hospitalization; Humans; Male; Middle Aged; Paroxetine; Proportional Hazards Models; Risk; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide, Attempted | 2010 |
Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors.
Topics: Antidepressive Agents, Tricyclic; Fluoxetine; Humans; Imipramine; Ion Channels; Molecular Conformation; Neurons; Paroxetine; Receptors, Cholinergic; Receptors, Nicotinic; Selective Serotonin Reuptake Inhibitors | 2010 |
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Antidepressive Agents, Second-Generation; Blood Pressure; Cross-Sectional Studies; Depression; Female; Fluoxetine; Gene Frequency; Heart Rate; Homozygote; Humans; Linear Models; Male; Paroxetine; Pharmacogenetics; Phenotype; Pilot Projects; Receptors, Adrenergic, beta-1; Retrospective Studies; Risk Assessment; Risk Factors; Selective Serotonin Reuptake Inhibitors; Young Adult | 2010 |
Utility of organotypic raphe slice cultures to investigate the effects of sustained exposure to selective 5-HT reuptake inhibitors on 5-HT release.
Topics: Action Potentials; Animals; Antidepressive Agents; Autoreceptors; Brain; Calcium; Citalopram; Extracellular Space; Fluoxetine; Hydroxyindoleacetic Acid; Organ Culture Techniques; Paroxetine; Raphe Nuclei; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Tryptophan Hydroxylase | 2010 |
Effects of selective serotonin reuptake inhibitors on GABAergic inhibition in the hippocampus of normal and pilocarpine induced epileptic rats.
Topics: Analysis of Variance; Animals; Citalopram; Electroencephalography; Epilepsy; Fluoxetine; gamma-Aminobutyric Acid; Hippocampus; Male; Neural Inhibition; Neurons; Paroxetine; Pilocarpine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Vesicular Inhibitory Amino Acid Transport Proteins | 2010 |
A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments.
Topics: Algorithms; Bias; Computer Simulation; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Linear Models; Medication Adherence; Models, Statistical; Multicenter Studies as Topic; Paroxetine; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.
Topics: Animals; Astrocytes; Brain; Cells, Cultured; Flow Cytometry; Fluoxetine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Paroxetine; Receptor, Serotonin, 5-HT2B; Selective Serotonin Reuptake Inhibitors; Signal Transduction | 2010 |
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies.
Topics: Adult; Antidepressive Agents, Second-Generation; Antifungal Agents; Antimalarials; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Clopenthixol; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Fluoxetine; Humans; In Vitro Techniques; Ketoconazole; Male; Methotrimeprazine; Microsomes, Liver; Middle Aged; Paroxetine; Quinidine | 2010 |
Characterization of 5-HT transporter and receptor system in HeLaS3 cells by [(3)H]8-OH-DPAT and other serotonergic ligands.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Binding, Competitive; Biogenic Amines; Cocaine; Fluoxetine; HeLa Cells; Humans; Kinetics; Ligands; Paroxetine; Radioligand Assay; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Vesicular Biogenic Amine Transport Proteins | 2011 |
Rapid HPLC method for the simultaneous monitoring of duloxetine, venlaflaxine, fluoxetine and paroxetine in biofluids.
Topics: Chromatography, High Pressure Liquid; Cyclohexanols; Duloxetine Hydrochloride; Fluoxetine; Humans; Limit of Detection; Paroxetine; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Thiophenes; Venlafaxine Hydrochloride | 2009 |
[Comparative efficacy of selective serotonin reuptake inhibitors in young prenatally stressed female rats].
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Female; Fluoxetine; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sexual Maturation; Stress, Psychological | 2010 |
Antidepressant use during pregnancy. FPIN’s clinical inquiries.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Cyclohexanols; Evidence-Based Medicine; Female; Fluoxetine; Humans; Odds Ratio; Paroxetine; Physicians, Family; Pregnancy; Pregnancy Complications; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Alcohol Drinking; Female; Finland; Fluoxetine; Heart Septal Defects, Ventricular; Humans; Middle Aged; Paroxetine; Pregnancy; Risk Assessment; Selective Serotonin Reuptake Inhibitors; United States; Young Adult | 2011 |
[Influence of fluoxetine and paroxetine on anxiety-like behavior in young and adult prenatally stressed male rats].
Topics: Age Factors; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Behavior, Animal; Female; Fluoxetine; Male; Paroxetine; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sex Factors; Stress, Psychological | 2011 |
[Approximate entropy of the placebo effect in clinical trials of newer antidepressants].
Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Placebo Effect; Placebos; Severity of Illness Index; Venlafaxine Hydrochloride | 2010 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors | 2011 |
Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction.
Topics: Adrenal Cortex Hormones; Age Factors; Aged; Anemia; Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Canada; Citalopram; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Heart Failure; Hemorrhage; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Neoplasms; Paroxetine; Peptic Ulcer; Platelet Aggregation Inhibitors; Renal Insufficiency; Retrospective Studies; Risk; Risk Factors; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors; Ticlopidine | 2011 |
Effects of periadolescent fluoxetine and paroxetine on elevated plus-maze, acoustic startle, and swimming immobility in rats while on and off-drug.
Topics: Acoustic Stimulation; Age Factors; Analysis of Variance; Animals; Body Weight; Brain; Corticosterone; Critical Period, Psychological; Dose-Response Relationship, Drug; Escape Reaction; Exploratory Behavior; Fluoxetine; Immobility Response, Tonic; Longitudinal Studies; Male; Maze Learning; Paroxetine; Rats; Reflex, Startle; Selective Serotonin Reuptake Inhibitors; Sensory Gating | 2011 |
The MMPI-2 neurotic triad subscales and depression levels after pharmacological treatment in patients with depressive disorders - clinical study.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder; Female; Fluoxetine; Humans; Hypochondriasis; Hysteria; Male; Middle Aged; MMPI; Neurotic Disorders; Observer Variation; Paroxetine; Psychometrics; Reproducibility of Results; Sertraline; Statistics as Topic; Young Adult | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors | 2011 |
Selective serotonin reuptake inhibitors and risk for major congenital anomalies.
Topics: Abnormalities, Drug-Induced; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Selective Serotonin Reuptake Inhibitors | 2012 |
Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system.
Topics: Animals; Antidepressive Agents; Coumaric Acids; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Immobility Response, Tonic; Ketanserin; Male; Mice; Motor Activity; Paroxetine; Piperazines; Pyridines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Antagonists; Sertraline | 2012 |
Chronic fluoxetine selectively upregulates dopamine D₁-like receptors in the hippocampus.
Topics: 5,7-Dihydroxytryptamine; Animals; Autoradiography; Benzazepines; Biophysics; Dopamine Antagonists; Electric Stimulation; Excitatory Postsynaptic Potentials; Fluoxetine; Hippocampus; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mossy Fibers, Hippocampal; Paroxetine; Patch-Clamp Techniques; Protein Binding; Receptors, Dopamine D1; Receptors, Serotonin; Serotonin Agents; Tritium; Up-Regulation | 2012 |
Role of 5-hydroxytryptamine2C receptors in marble-burying behavior in mice.
Topics: Aminopyridines; Amphetamines; Animals; Behavior, Animal; Fluoxetine; Indoles; Male; Mice; Mice, Inbred ICR; Motor Activity; Obsessive-Compulsive Disorder; Paroxetine; Receptor, Serotonin, 5-HT2C; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists | 2012 |
High venlafaxine serum levels after prior fluoxetine medication.
Topics: Antidepressive Agents, Second-Generation; Cholinergic Antagonists; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2012 |
The declining use of reboxetine in years 2000 to 2006: a pharmacoepidemiological comparative study.
Topics: Antidepressive Agents; Depression; Fluoxetine; Humans; Morpholines; Paroxetine; Pharmacoepidemiology; Practice Patterns, Physicians'; Publication Bias; Reboxetine; Selective Serotonin Reuptake Inhibitors | 2012 |
A simple HPLC method for the simultaneous determination of two selective serotonin reuptake inhibitors and two serotonin-norepinephrine reuptake inhibitors in hair, nail clippings, and cerebrospinal fluid.
Topics: Adrenergic Uptake Inhibitors; Biological Transport; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Cyclohexanols; Duloxetine Hydrochloride; Fluoxetine; Hair; Humans; Nails; Norepinephrine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Venlafaxine Hydrochloride | 2012 |
Comparison of two extraction methods for the determination of selective serotonin reuptake inhibitors in sewage sludge by hollow fiber liquid-phase microextraction.
Topics: Chromatography, Liquid; Citalopram; Fluoxetine; Liquid Phase Microextraction; Mass Spectrometry; Paroxetine; Porosity; Selective Serotonin Reuptake Inhibitors; Sertraline; Sewage; Surface Properties | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
Fluoxetine suppresses synaptically induced [Ca²⁺]i spikes and excitotoxicity in cultured rat hippocampal neurons.
Topics: Animals; Calcium Channel Blockers; Calcium Signaling; Cell Death; Cells, Cultured; Citalopram; Excitatory Amino Acid Agonists; Exocytosis; Female; Fluoxetine; Hippocampus; Magnesium Deficiency; Neurons; Neuroprotective Agents; Neurotransmitter Agents; p-Chloroamphetamine; Paroxetine; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Selective Serotonin Reuptake Inhibitors; Serotonin Agents; Synapses | 2013 |
Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task.
Topics: Acetamides; Adrenergic alpha-2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Choice Behavior; Cyclobutanes; Cyclohexanols; Fluoxetine; Hypnotics and Sedatives; Idazoxan; Impulsive Behavior; Male; Norepinephrine; Paroxetine; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2013 |
Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells.
Topics: Animals; Apoptosis; Cell Death; Cell Line; Diabetes Mellitus; Fluoxetine; Humans; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Signal Transduction; Unfolded Protein Response | 2013 |
The pro-inflammatory cytokine TNF-α regulates the activity and expression of the serotonin transporter (SERT) in astrocytes.
Topics: Astrocytes; Cell Line, Tumor; Citalopram; Fluoxetine; Glioma; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Paroxetine; Pyridines; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tumor Necrosis Factor-alpha | 2013 |
Influence of body mass index on the choice of therapy for depression and follow-up care.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; Depression; Female; Fluoxetine; Follow-Up Studies; Humans; Logistic Models; Male; Mianserin; Middle Aged; Mirtazapine; Obesity; Paroxetine; Psychotherapy; Young Adult | 2013 |
The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Canada; Child; Child, Preschool; Citalopram; Databases, Factual; Fluoxetine; Fluvoxamine; Humans; Infant; Mental Disorders; Paroxetine; Practice Patterns, Physicians'; Selective Serotonin Reuptake Inhibitors; Sertraline | 2013 |
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Topics: Antidepressive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Enzyme Inhibitors; Female; Fluoxetine; Humans; Netherlands; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen | 2013 |
Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Depression; Fluoxetine; Guinea Pigs; Mice; Motor Activity; Olfactory Bulb; Paroxetine; Quinoxalines; Rats; Rats, Wistar; Serotonin 5-HT3 Receptor Antagonists; Swimming | 2013 |
Antidepressants and testicular cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; California; Case-Control Studies; Cohort Studies; Depression; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Testicular Neoplasms; Young Adult | 2014 |
Effects of antidepressant drugs on synaptic protein levels and dendritic outgrowth in hippocampal neuronal cultures.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Enlargement; Cells, Cultured; Citalopram; Dendrites; Fluoxetine; Hippocampus; Imipramine; Nerve Tissue Proteins; Neurons; Paroxetine; Rats; Rats, Sprague-Dawley; Sertraline; Thiazepines; Tranylcypromine | 2014 |
Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
Topics: 5-Hydroxytryptophan; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antidepressive Agents; Benzofurans; Brain; Citalopram; Dose-Response Relationship, Drug; Drug Interactions; Extracellular Space; Fluoxetine; Indoles; Male; Paroxetine; Piperazines; Pyridines; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Serotonin Receptor Agonists; Vilazodone Hydrochloride | 2014 |
Antidepressants and testicular cancer: cause versus association.
Topics: Adult; Data Interpretation, Statistical; Data Mining; Fluoxetine; Humans; Male; Meta-Analysis as Topic; Paroxetine; Research Design; Selective Serotonin Reuptake Inhibitors; Testicular Neoplasms | 2014 |
Editorial Comment from Dr Sato to Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation.
Topics: Fluoxetine; Humans; Male; Melatonin; Paroxetine; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Sertraline | 2014 |
Editorial Comment from Dr Amano to Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation.
Topics: Fluoxetine; Humans; Male; Melatonin; Paroxetine; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Sertraline | 2014 |
Response to Editorial Comments to Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation.
Topics: Fluoxetine; Humans; Male; Melatonin; Paroxetine; Premature Ejaculation; Selective Serotonin Reuptake Inhibitors; Sertraline | 2014 |
Effects of acute administration of selective serotonin reuptake inhibitors on sympathetic nerve activity.
Topics: Animals; Antidepressive Agents; Arterial Pressure; Baroreflex; Cardiovascular Physiological Phenomena; Fluoxetine; Heart Rate; Kidney; Male; Paroxetine; Rats, Wistar; Respiratory Rate; Selective Serotonin Reuptake Inhibitors; Sertraline; Sympathetic Nervous System; Vital Signs | 2014 |
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Prospective Studies; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Child; Citalopram; Databases, Factual; Drug Monitoring; Drug Utilization; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Norway; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2015 |
Paroxetine differentially modulates LPS-induced TNFα and IL-6 production in mouse macrophages.
Topics: Animals; Cell Line; Fluoxetine; Interleukin-6; Lipopolysaccharides; Lysergic Acid; Macrophages; Mice, Inbred C57BL; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Tumor Necrosis Factor-alpha | 2015 |
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Pain; Paroxetine; Prospective Studies; Quality of Life; Regression Analysis; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome | 2016 |
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2015 |
Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.
Topics: Age Factors; Animals; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Male; Maze Learning; Mood Disorders; Paroxetine; Rats; Rats, Sprague-Dawley; Sensory Gating; Treatment Outcome | 2015 |
Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay.
Topics: Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Citalopram; Estradiol; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Progesterone; Selective Serotonin Reuptake Inhibitors; Sertraline; Testosterone | 2015 |
Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs.
Topics: Analgesics; Antidepressive Agents; Citalopram; Dose-Response Relationship, Drug; Fluoxetine; HEK293 Cells; Humans; Membrane Potentials; Moclobemide; Monoamine Oxidase Inhibitors; NAV1.7 Voltage-Gated Sodium Channel; NAV1.8 Voltage-Gated Sodium Channel; Paroxetine; Patch-Clamp Techniques; Selective Serotonin Reuptake Inhibitors; Sodium Channel Blockers; Time Factors; Transfection | 2015 |
Paroxetine suppresses recombinant human P2X7 responses.
Topics: Animals; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Clomipramine; Dose-Response Relationship, Drug; Fluoxetine; Humans; Interleukin-1beta; Lipopolysaccharide Receptors; Mice; Monocytes; Paroxetine; Purinergic P2X Receptor Agonists; Purinergic P2X Receptor Antagonists; Rats; Receptors, Purinergic P2X7; Recombinant Proteins; Trifluoperazine | 2015 |
Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Topics: Adolescent; Adult; Antidepressive Agents; Child; Child, Preschool; Citalopram; Cohort Studies; Databases, Factual; Depression; Dose-Response Relationship, Drug; Drug Labeling; Drug Prescriptions; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Practice Guidelines as Topic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index; Suicide, Attempted; United States; United States Food and Drug Administration; Young Adult | 2016 |
Comparison of the Efficiency of Adeprophen and Antidepressants of Various Groups on the Model of Reserpine-Induced Depression in Rats.
Topics: Adenine; Amitriptyline; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Fluoxetine; Food Preferences; Imipramine; Male; Motor Activity; Paroxetine; Rats; Reserpine; Sertraline; Venlafaxine Hydrochloride | 2016 |
Differential Associations of Specific Selective Serotonin Reuptake Inhibitors With Resting-State Heart Rate and Heart Rate Variability: Implications for Health and Well-Being.
Topics: Adult; Aged; Brazil; Citalopram; Electrocardiography; Female; Fluoxetine; Heart Rate; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2016 |
Effects of antidepressants on P2X7 receptors.
Topics: Adenosine Triphosphate; Animals; Antidepressive Agents; Depressive Disorder; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; HEK293 Cells; Humans; Paroxetine; Patch-Clamp Techniques; Platelet Aggregation Inhibitors; Rats; Receptors, Purinergic P2X7 | 2016 |
Exposure to SSRI-type antidepressants increases righting time in the marine snail Ilyanassa obsoleta.
Topics: Animals; Antidepressive Agents; Fluoxetine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Snails; Venlafaxine Hydrochloride | 2017 |
Alternative splicing of SMPD1 coding for acid sphingomyelinase in major depression.
Topics: Adult; Aged; Alternative Splicing; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Female; Fluoxetine; Gene Expression Regulation, Enzymologic; Humans; Male; Middle Aged; Paroxetine; Polymerase Chain Reaction; Sphingomyelin Phosphodiesterase | 2017 |
The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
Topics: Aged; Anti-Arrhythmia Agents; Cytochrome P-450 CYP2D6; Drug Interactions; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2017 |
BiteStrip analysis of the effect of fluoxetine and paroxetine on sleep bruxism.
Topics: Adult; Anxiety; Dental Devices, Home Care; Depression; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep Bruxism; Treatment Outcome | 2017 |
Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications.
Topics: Child; Child, Preschool; Citalopram; Coma; Dose-Response Relationship, Drug; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies; Hospitalization; Humans; Infant; Male; Paroxetine; Poison Control Centers; Retrospective Studies; Seizures; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Vilazodone Hydrochloride | 2017 |
Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder; Doxepin; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Morpholines; Paroxetine; Patient Acceptance of Health Care; Reboxetine; Selective Serotonin Reuptake Inhibitors; Stroke; Treatment Outcome | 2017 |
Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function.
Topics: Animals; Citalopram; Depression; Fluoxetine; Hindlimb Suspension; Male; Mice, Inbred C57BL; Mice, Inbred DBA; Paroxetine; Protein Binding; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Species Specificity; Swimming; Synaptosomes | 2017 |
Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography.
Topics: Chromatography, Liquid; Drug Monitoring; Fluoxetine; Humans; Paroxetine; Solid Phase Microextraction | 2017 |
Animal Behavior Case of the Month.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Behavior, Animal; Diazepam; Dog Diseases; Dogs; Fear; Fluoxetine; Gabapentin; Male; Noise; Paroxetine; Phobic Disorders | 2017 |
Depressive symptoms, monoamines levels, MAO-B activity and effect of treatment in a subset of depressed individuals from government sector hospital at Karachi.
Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Case-Control Studies; Depression; Female; Fluoxetine; Homovanillic Acid; Hospitals, Public; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Monoamine Oxidase; Pakistan; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Suicidal Ideation; Treatment Outcome; Young Adult | 2017 |
[Exploring the clinical characters of Shugan Jieyu capsule through text mining].
Topics: Anxiety; Data Mining; Depression; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Fluoxetine; Humans; Paroxetine; Sertraline | 2017 |
Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly.
Topics: Aged; Aged, 80 and over; Citalopram; Cohort Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Prescriptions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metoprolol; Middle Aged; Mirtazapine; Netherlands; Paroxetine | 2018 |
Negative myoclonus secondary to paroxetine intake.
Topics: Aged; Electroencephalography; Fluoxetine; Humans; Male; Medical Errors; Myoclonus; Paroxetine; Seizures; Selective Serotonin Reuptake Inhibitors; Somatosensory Cortex; Treatment Outcome | 2018 |
Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Topics: Altitude Sickness; Animals; Antidepressive Agents; Brain; Citalopram; Dopamine; Female; Fluoxetine; Male; Paroxetine; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2018 |
Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms: A Pharmacoepidemiological Study.
Topics: Antidepressive Agents; Basal Ganglia Diseases; Bupropion; Case-Control Studies; Citalopram; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pharmacoepidemiology; Sertraline; United States; Venlafaxine Hydrochloride | 2018 |
Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Citalopram; Epithelial Cells; Fluoxetine; Paroxetine; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sertraline; Swine | 2018 |
A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice.
Topics: Adult; Anticonvulsants; Female; Fluoxetine; Humans; Male; Medical Records; Middle Aged; Outpatients; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic; Topiramate; Treatment Outcome; United States; United States Department of Veterans Affairs; Venlafaxine Hydrochloride | 2018 |
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Monte Carlo Method; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2019 |
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression.
Topics: Adult; Aged; Aged, 80 and over; Animals; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Receptors, Serotonin; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult | 2020 |
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy.
Topics: Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydroxyzine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Syndrome; Young Adult | 2020 |
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Longitudinal Studies; Outcome Assessment, Health Care; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index | 2019 |
Storage of urine specimens in point of care (POC) urine drug testing cups reduces concentrations of many drugs.
Topics: Amitriptyline; Chromatography, Liquid; Drug Storage; Fentanyl; Flunitrazepam; Fluoxetine; Humans; Mass Spectrometry; Nortriptyline; Paroxetine; Point-of-Care Testing; Sertraline | 2019 |
Serotonin and serotonin reuptake inhibitors alter placental aromatase.
Topics: Aromatase; Cells, Cultured; Citalopram; Female; Fluoxetine; Humans; Molecular Docking Simulation; Paroxetine; Placenta; Pregnancy; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Trophoblasts; Venlafaxine Hydrochloride | 2019 |
Inhibitory and Stimulatory Effects of Selective Serotonin Reuptake Inhibitors on Cytochrome P450 2D6-mediated Dopamine Formation from p-Tyramine.
Topics: Cytochrome P-450 CYP2D6; Dopamine; Fluoxetine; Humans; Molecular Structure; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tyramine | 2019 |
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Least-Squares Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome | 2020 |
[Pharmacokinetics of antidepressants during pregnancy].
Topics: Antidepressive Agents; Cytochrome P-450 CYP2D6; Female; Fluoxetine; Humans; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors | 2020 |
Evidence-based prescribing for post-traumatic stress disorder.
Topics: Evidence-Based Medicine; Fluoxetine; Humans; Paroxetine; Sertraline; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride | 2020 |
Comparing Medications for DSM-5 PTSD in Routine VA Practice.
Topics: Acute Disease; Adult; Carbonic Anhydrase Inhibitors; Female; Fluoxetine; Humans; Male; Medication Adherence; Outcome Assessment, Health Care; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic; Topiramate; United States; United States Department of Veterans Affairs; Venlafaxine Hydrochloride | 2020 |
Low SSRI dosing in clinical practice-a register-based longitudinal study.
Topics: Child; Citalopram; Fluoxetine; Humans; Longitudinal Studies; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline | 2021 |
In vitro synergistic effects of fluoxetine and paroxetine in combination with amphotericin B against Cryptococcus neoformans.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Cryptococcosis; Cryptococcus neoformans; Drug Synergism; Drug Therapy, Combination; Fluoxetine; Humans; Meningoencephalitis; Microbial Sensitivity Tests; Microbial Viability; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2021 |
Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Topics: Alleles; Catalysis; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Ligands; Molecular Docking Simulation; Paroxetine; Quinidine; Terbinafine | 2022 |
Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors.
Topics: Adult; Aged; Analgesics, Opioid; Cohort Studies; Comorbidity; Depression; Emergency Medical Services; Female; Fluoxetine; Hospitalization; Humans; Male; Middle Aged; Opiate Overdose; Oxycodone; Pain; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2022 |
Antidepressants Are Poor Inhibitors of Heat-Evoked Ion Currents Mediated by TRPM2.
Topics: Adenosine Diphosphate Ribose; Amitriptyline; Animals; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Fluoxetine; HEK293 Cells; Hot Temperature; Humans; Ketamine; Lidocaine; Mice; Paroxetine; Pregabalin; Sertraline; TRPM Cation Channels | 2022 |
SSRI antidepressants differentially modulate serotonin reuptake and release in Drosophila.
Topics: Animals; Antidepressive Agents; Citalopram; Drosophila; Drosophila melanogaster; Fluoxetine; Mammals; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin | 2022 |
Effects of central nervous system drugs on androgen, estrogen α, glucocorticoid, and thyroid receptors.
Topics: Androgens; Animals; Carbamazepine; Central Nervous System Agents; CHO Cells; Clonazepam; Cricetinae; Cricetulus; Estrogen Receptor alpha; Estrogens; Fluoxetine; Glucocorticoids; Luciferases, Firefly; Paroxetine; Receptors, Androgen; Receptors, Glucocorticoid; Sertraline; Thyroid Gland | 2022 |
The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.
Topics: Case-Control Studies; Citalopram; Cohort Studies; Death, Sudden, Cardiac; Dialysis Solutions; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Potassium; Renal Dialysis; Selective Serotonin Reuptake Inhibitors; Sertraline; United States | 2022 |
Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Topics: Antidepressive Agents; Atenolol; Bisoprolol; Bupropion; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Prescriptions; Fluoxetine; Humans; Metoprolol; Paroxetine; Retrospective Studies | 2022 |
Association between CYP metabolizer phenotypes and selective serotonin reuptake inhibitors induced weight gain: a retrospective cohort study.
Topics: Body Weight; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Humans; Paroxetine; Phenotype; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Weight Gain | 2022 |
Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths.
Topics: Adolescent; Antipsychotic Agents; Citalopram; Diabetes Mellitus, Type 2; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Sertraline | 2022 |
Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Topics: Adolescent; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Paroxetine; Pharmaceutical Preparations; Quality of Life | 2022 |
Using filled prescription sequences to rank antidepressants: A nationwide replication study.
Topics: Antidepressive Agents; Citalopram; Fluoxetine; Humans; Paroxetine; Venlafaxine Hydrochloride | 2023 |
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Fluoxetine; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 2023 |
The antidepressant-like effects of escitalopram in mice require salt-inducible kinase 1 and CREB-regulated transcription co-activator 1 in the paraventricular nucleus of the hypothalamus.
Topics: Animals; Antidepressive Agents; Depression; Escitalopram; Fluoxetine; Humans; Mice; Paraventricular Hypothalamic Nucleus; Paroxetine; Serotonin; Stress, Psychological | 2023 |